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ABSTRACT 
Discerning the Role of Prostaglandins in Ductus Arteriosus Remodeling 
Artiom Gruzdev 
 (Under the direction of Dr. Beverly H. Koller) 
 
 The ductus arteriosus (DA) is a fetal pulmonary bypass shunt that constricts and 
permanently remodels during the transition from fetal to adult circulation. Prostaglandin E2 
(PGE2) is potent mediator of numerous physiological responses both in homeostasis and 
disease state. PGE2 play a vital role in DA maturation and closure, although the exact 
molecular role is unclear. We attempt to discern the nature of PGE2 involvement in DA 
maturation and closure. Here we generate a conditional null allele of the prostaglandin E 
receptor 4 (EP4), which has been previously shown to be responsible for PGE2 signaling in 
the DA. Utilizing various tissue specific Cre recombinase transgenes, we have shown that 
EP4 expression on the neural crest derived smooth muscle cells of the DA is critical for 
proper DA closure. We have also shown that endothelial expression of the PGE2 vasodilatory 
receptors (EP4 and EP2) is non-essential for DA closure or vascular development. 
 Genome wide expression profiling of the wildtype DA and EP4 deficient DA were 
used to assess the transcriptional consequences of PGE2/EP4 signaling in the DA. 
Differentially expressed genes in the wildtype DA indicate that EP4 receptor expression 
leads to the up-regulation of numerous cytoskeletal genes. The relative minor increase (<2 
 iv 
fold) of numerous cytoskeletal genes may explain why the wildtype and EP4 deficient DA 
appear morphologically similar in utero but have antithetical fates after birth. 
 Here we also document the existence of a prostaglandin-independent mechanism of 
DA maturation and closure in mice. Selective mating generated a recombinant inbred (RI) 
mouse strain that undergoes DA maturation and closure without any contribution from 
prostaglandin signaling. Single locus inheritance of patent ductus arteriosus (PDA) in 
common inbred strains (CIS) seemed at odds with the complex inheritance pattern of PDA in 
larger animals, but the RI strain indicates that DA closure in non-CIS mice is also a complex 
trait. The study of both prostaglandin-dependent DA closure of CIS mice and prostaglandin-
independent DA closure of RI mice provides a mouse model for understanding the complex 
trait of larger animals. 
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Chapter 1 
 
Introduction 
 
2	  	  
The mammalian cardio-pulmonary system 
The work presented in this dissertation is focused on the closure of the ductus 
arteriosus, a critical event in the transition from fetal circulation to adult circulation. It is 
therefore beneficial to briefly describe the adult and fetal circulatory systems, and the 
transition that must occur at birth for the proper establishment of the adult circulatory system. 
The mammalian cardio-pulmonary system is responsible for systemic circulation and 
respiration, two distinct functions that are often treated as one. Systemic circulation carries 
oxygenated blood from the left side of the heart to the body, and returns de-oxygenated 
venous blood to the right side of the heart. Pulmonary circulation is the sole source of 
respiration in adult mammals. Pulmonary circulation brings O2 depleted, CO2 rich blood to 
the lungs from the right side of the heart for gas exchange, and returns oxygenated blood to 
the left side of the heart. Separation of pulmonary circulation and systemic circulation has 
two main advantages over having heart, respiration, and systemic circulation in series. High 
respiration efficiency occurs when the pulmonary and systemic circulations are separate, as 
oxygenated and de-oxygenated blood cannot readily mix. Another key advantage of 
separating pulmonary and systemic circulation is the ability to keep the two systems at 
different pressure. The lungs provide significant resistance to blood flow, and greatly reduce 
pressure in pulmonary venous blood flow compared to the pressure of pulmonary arterial 
blood flow. If pulmonary circulation and systemic circulation were in series, low-pressure 
oxygenated blood from the lungs would have to provide O2 to the body, which would likely 
result in extreme hypoxia given the great oxygen demands of the body.  
A starting point for the circular flow of blood through the adult circulatory system is 
arbitrary, given the fact that the system, as it name implies, is circular. Therefore, the point at 
3	  	  
which carbon dioxide rich, de-oxygenated venous blood returns to the heart through the 
venae cavae will be used as the starting point. In the adult circulatory system, the inferior 
vena cava and superior vena cava return blood to the right atrium from the lower and upper 
extremities, respectively. Venae cavae blood mixes in the atrium, and atrial contraction 
expels the blood into the right ventricle through the tricuspid valve. Right ventricular 
contraction propels blood, through the pulmonary valve, to the lungs where a network of 
capillaries will be the site of gas exchange between the oxygen rich air filled alveoli of the 
lungs and the carbon dioxide rich blood in the capillaries. The pulmonary veins return arterial 
blood to the left atrium, and contraction of the left atrium propels blood into the left ventricle 
through the mitral valve. Left ventricular contraction expels blood, through the aortic valve, 
into the aortic arch for systemic circulation. In the adult heart, the left and right sides of the 
heart function as two distinct pumps. The right side of the heart collects systemic venous 
blood flow and pumps it to the pulmonary system for respiration. The left side of the heart 
collects arterial blood from the lungs, and pumps it to the rest of the body for systemic 
circulation. All amniotic animals (birds, mammals, and reptiles) share this basic layout of 
circulation and respiration. 
 
Evolution of the cardiovascular-respiratory system of vertebrata 
To appreciate the mammalian system of circulation and respiration, it helps to have a 
frame of reference. Therefore, a brief synopsis of the cardiovascular-respiratory system 
found in other vertebrates is provided here to illustrate other respiratory mechanisms found in 
nature and the uniqueness of pulmonary respiration of amniotes.  
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All mammals, including human’s most distant extant relative the Platypus 
(Ornithorhynchus anatinus), have a remarkably similar cardio-pulmonary system [1, 2]. In 
fact, the respiratory system of all amniotes, whether from a mammal, bird, or reptiles, is 
functionally very similar. Phylogenetic studies indicate that the ancestors of all extant 
amniotes shared many cardiovascular similarities with amphibians [3]. In turn, amphibians 
share many similarities with fish, our most distant extant vertebrate relative [3]. Like 
amniotes, fish and amphibians have a crucial need of O2, but their respiratory mechanism is 
remarkably different from amniotes. 
The development stages of fish are well documented, and there are several key stages 
that fish undergo from zygote to adult that involve a transition of the site of respiration [4]. 
The first stages of development occur before hatching, and although a heart is present in the 
pre-hatching embryo, O2 and CO2 exchange occurs through diffusion [5]. In many fish 
species, the transition from egg to free-feeding larvae occurs before the maturation of the 
gills and circulatory system, and simple diffusion accounts for most of the gas exchange of 
the free-feeding larvae [5]. As growth continues, the circulatory system matures and the gills 
become a more important respiratory organ. Diffusion will eventually become insufficient in 
providing gas exchange and the gills will become the sole site for respiration in most fish. 
The gills are well suited for water-breathing, but would collapse in air, increasing vascular 
resistance blocking systemic circulation, therefore terrestrial life requires an alternate 
respiratory organ. Gills of fish are also ill suited for respiration during period of extreme 
exercise and fish must either switch to air-breathing organs or suffer hypoxia during period 
of strenuous exercise [6, 7]. 
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The lungfish, as their name implies, have lungs similar to that of obligate air-
breathing animals. With few exceptions, the larval and juvenile lungfish develops with 
functional gills, and adult lungfish that maintain their neotenic gills can use gills exclusively 
for respiration in oxygen rich waters [8]. Lungfish destined to become obligate air-breathers 
initiate pulmonary respiration while the gills are still functional [8]. Lungfish possess a 
pulmonary bypass system consisting of an arterial duct and pulmonary artery vasomotor 
segment (PAVS) [9]. A closed arterial duct and open PAVS enables gill circulation, while an 
open arterial duct and closed PAVS enables pulmonary circulation. The arterial duct of adult 
lungfish is capable of channeling blood to either the gills or the pulmonary system depending 
on environmental conditions [9]. The free-feeding fish, from larvae to adult, can have up to 
three different respiratory organs (cutaneous, gills, or lung) through their life cycle, with two 
of the three organs functional at the same time in development.  
The cardio-respiratory system of amphibians at various times in development 
resembles both the aquatic respiration of fish and pulmonary respiration of terrestrial 
animals. The amphibian larvae closely resemble fish as hatching usually occurs in an 
aqueous environment and the amphibian larvae relies on simple diffusion and gills for 
respiration. Some amphibians retain neotenic gills due to environmental pressure, but most 
adult amphibians do not have functional gills after metamorphosis [10]. In adult amphibians, 
blood returns to the right atrium oxygenated via cutaneous respiration, and pulmonary veins 
return oxygenated blood from the lungs to the left atrium [11]. The Plethodontidae (the 
lungless salamanders) and some species of frog do not have any lungs and rely exclusively 
on cutaneous respiration [12, 13]. Cutaneous respiration is found in virtually all amphibians 
and can account for 30-100% of the oxygen needs of the animal [14]. A pulmonary bypass 
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exists in some amphibians shunting blood from the pulmonary artery to the respiratory 
lamellae in the gills, and the pulmonary bypass in adults is usually not occluded [15]. In 
amphibians, pulmonary respiration develops while an alternate organ provides the site of gas 
exchange. 
While amphibians undergo metamorphosis to transition to terrestrial life, it was the 
evolution of the amniotic egg that allows terrestrial life in all stages of development [16]. 
Amniotes include mammals (oviparous or viviparous), birds (oviparous), and reptiles 
(oviparous or oviviparous). Regardless of method parturition or hatching, the transition from 
fetus to neonate of all amniotes includes the initiation of pulmonary circulation without a 
redundant secondary site of respiration like that seen in fish and amphibians. Unlike 
amphibians and lungfish in which pulmonary respiration develops in free-swimming larvae, 
the pulmonary system of the amniotes must be functional at the time of birth. After birth or 
hatching there is a cessation of placental respiration or chorioallantoic respiration, 
respectively, and pulmonary respiration must provide all gas exchange for the amniotic 
neonate. 
 
Transition from fetal to adult circulation by placental mammals 
 Amniotic development occurs in an aqueous environment, regardless if that 
environment is the uterus or the egg. Placental and metatheria mammals rely on placenta 
blood flow for fetal gas exchange, and avian, reptile, and monotreme fetuses rely on the gas 
permeability of the eggshell for gas exchange [17]. What all amniotes share is that at some 
point, whether it is at hatching, birth, or migration to the marsupium, the fluid-filled lungs 
must be cleared of liquid and the newborn must begin pulmonary respiration [18, 19]. While 
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there are many similarities in all amniotes, there are also significant differences between 
birth, hatching, and migration to the marsupium. Therefore the remainder of this chapter will 
focus on the cardio-pulmonary system and transition from fetal circulation to adult 
circulation of placental mammals [20]. 
 In the adult circulatory system, total right cardiac output enters the pulmonary system 
for respiration. The fetal lungs are incompatible with the circulatory system of the adult 
because the fluid filled fetal lungs are resistant to blood flow and to prevent fetal pulmonary 
hypertension the majority of cardiac output must bypass the lungs [21-23]. The fetal 
circulatory system has evolved with two right-to-left shunts, the foramen ovale and the 
ductus arteriosus (DA), that allow blood to bypass fetal pulmonary circulation.  
 In utero respiration occurs in the placenta between maternal circulation and fetal 
circulation. The fetal heart and fetal pulmonary system do not play a role in respiration, and 
the fetal lungs are non-essential organs in utero. Oxygenated blood from the placenta enters 
the right atrium via the inferior vena cava and is preferentially channeled through the 
foramen ovale to the left atrium (See Figure 1.1 for fetal and adult cardio-pulmonary 
circulation). The foramen ovale is an intracardiac shunt in the atrial septum. The flap like 
shunt allows blood to flow down a concentration gradient from the higher-pressure right 
atrium to lower pressure left atrium [24, 25]. There is preferential channeling of inferior vena 
cava blood flow (versus superior vena cava blood flow) through the foramen ovale [26]. 
Approximately 60% of the right atrial blood flow is shunted through the foramen ovale. 
From the left atrium, blood is pumped through the mitral valve into the left ventricle. Left 
ventricular contraction sends blood to the aortic arch, with preferential blood flow to the 
upper extremities via the ascending aorta.  
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Blood returning to the heart from the superior vena cava, enters the right atrium and is 
preferentially channeled to the right ventricle (~40% of right atrial input).  Right ventricular 
contraction expels blood into the pulmonary duct. The pulmonary duct sends as little as 10% 
of right ventricular output to the pulmonary arteries and fetal lungs. The remaining blood is 
shunted away from pulmonary circulation into the descending aorta via the DA [24, 27]. The 
DA is a smooth muscle lined arterial vessel that in utero provided right-to-left shunting of 
blood from the right ventricle to the descending aorta, bypassing pulmonary circulation. 
Blood flow through the descending aorta is directed to inferior systemic circulation and 
placental circulation.  
At birth, the neonatal lung clears liquid from the lung mainly through transepithelial 
sodium reabsorption [19, 28]. The fluid free neonatal lung is capable of inflation, which 
decreases resistance to pulmonary blood flow. A drop in resistance to pulmonary blood flow 
by itself is the first step in the transition from fetal to adult circulation.  Once the lungs are 
capable of inflation and more importantly respiration, the pulmonary bypass via the foramen 
ovale and the DA must be attenuated and eventually occluded to complete the transition to 
adult circulation [20].  
 Clearing of liquid from the lungs allows the lungs to inflate and deflate which 
decreases resistance to pulmonary blood flow [29]. Right ventricular output shifts from the 
DA to the pulmonary arteries as pulmonary resistance drops [30]. The increase in pulmonary 
blood flow decreases pressure in the DA and allows shunting of descending aorta blood flow 
through the DA, a reversal of fetal right-to-left shunting [31]. An obvious consequence of 
increased pulmonary circulation input is an increase in pulmonary circulation output, which 
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increases pressure in the left atrium, and causes physical closure of the foramen ovale [32]. 
Closure of the foramen ovale places the right atrium and ventricle in series.  
The initial closure of the foramen ovale occurs because of an increase in blood flow 
to the left atrium from the pulmonary veins [25]. Typically, the foramen ovale will fuse with 
the atrial septum within the first year of life, eventually leaving only the fossa ovalis, an 
embryological remnant of the foramen ovale [32]. Permanent fusion of the foramen ovale 
with the atrial septum does not occur in almost 25% of the general population, but failure of 
fusion is asymptomatic in most people because of the physical closure caused by the 
pulmonary circulation output to the left atrium [32]. Symptomic patent foramen ovale has 
been linked to migraines and ischemic stroke [33, 34].  
 Right ventricular output is still connected to the descending aorta via a patent DA. 
Basic fluid dynamics can be used to describe the situation occurring in the heart with a patent 
DA. High-pressure blood flow in the descending aorta and high-pressure right ventricular 
output directly oppose each other, with only the low-pressure pulmonary arteries as a 
common exhaust. Descending aorta pressure is initially higher than right ventricular output 
pressure so there is a reversal of blood flow through the DA (left-to-right shunting)	  [29]. The 
DA typically constricts within the first 24 hours of life and remodels into a ligament 
(Ligamentum arteriosum) within the first 3 weeks of life (varies by species) [29]. Following 
closure of the DA, the transition from fetal cardiac blood flow to adult cardiac blood flow is 
completed. The left atrium, left ventricle, pulmonary system, right atrium, right ventricle, 
aortic arch, and systemic circulation are all in series. It is noteworthy to mention that the 
closure of the DA and foramen ovale is timed to occur right after birth not just for the 
prevention of pulmonary hypertension. In utero, the patent DA and foramen ovale allows all 
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four chambers of the heart to develop with an active workload, and heart valve development 
is dependent on blood flow patterns similar to the adult circulation [35, 36]. 
In humans, failure of DA closure within 72 hours is diagnostically considered a 
persistently patent DA (PDA). PDA result in an increase in pulmonary blood flow as right 
and left ventricular output enters pulmonary circulation through the pulmonary duct and DA, 
respectively. This creates inefficiency in the pulmonary system as oxygenated blood from the 
descending aorta is channeled through the DA (left-to-right shunting) and enters the 
pulmonary system for a second round of gas exchange. The internal diameter of PDA 
directly correlated to the severity of any symptoms. A PDA with a small diameter may be 
completely asymptomatic throughout an individual’s life, and spontaneous closure is not 
uncommon [37]. However, a PDA with a large diameter typically results in two undesirable 
synergistic affects, pulmonary hypertension and chronic hypoxia. 
 If closure of a large PDA does not occur, pulmonary hypertension can result from an 
increase in blood flow to the lungs from the left-to-right shunting through the DA [38]. 
Increased pulmonary pressure can damage the delicate capillaries responsible for gas-
exchange, resulting in vessel thickening and formation of scar tissue [39]. As pulmonary 
circulation resistance increases, right ventricular workload increases causing right ventricular 
hypertrophy, which further results in an increase in pulmonary hypertension [40]. As 
pulmonary hypertension increases, the pulmonary arterioles and capillaries thicken and 
remodel, decreasing gas exchange efficiency. In severe cases of chronic hypoxia, 
polycythemia will occur as more red blood cells are produced to counter the chronic hypoxia 
[41, 42]. The resulting hyper-viscosity of blood further increases workload on the right 
ventricle [43]. Increasing right ventricular hypertrophy and increasing resistance to 
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pulmonary blood flow can ultimately result in the reversal of blood flow through the DA, 
restoring pulmonary bypass (right-to-left shunting) in an adult. This occurs when right 
ventricular output minus pulmonary blood flow is at a higher pressure than the descending 
aorta.  
 Symptomatic PDA in humans can manifest itself as pulmonary hypertension caused 
primarily by increased resistance, pulmonary edema and hemorrhage, congestive heart 
failure, intraventricular hemorrhage, bronchopulmonary dysplasia, and death [38, 44]. Given 
the possible consequences of PDA, treatment of any diameter PDA is currently common 
practice. Treatment options for PDA include surgical ligation of the DA, transcatheter 
placement of an intravascular coil to occlude blood flow through the DA, and 
pharmacological inhibition of prostaglandin production in hopes of initiating normal DA 
closure. Surgical and transcatheter closure have become routine procedures and have a 
success rate of nearly 100%, but the procedures carry the same risks as other surgical or 
transcatheter procedures. Pharmacological treatment is currently only an option in neonates 
and infants, and its efficacy is highly variable, and may cause serious side effects without 
inducing DA closure. 
   
Characteristics and closure of the ductus arteriosus  
Giulio Cesare Aranzi first described the DA over 400 years ago, but the molecular 
pathways responsible for its closure are still unclear. The DA develops from the sixth aortic 
artery in mammals, and in utero morphologically resembles other great arteries of the heart. 
The DA, like all major arteries, can be subdivided into 4 layers: an internal endothelium, 
surrounded by the tunica intima (composed of internal elastic lamina and fibrocollagenous 
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tissue), a thick tunic media of smooth muscle cells, and an external tunica adventitia 
(comprised of fibrocollagenous tissue and external elastic lamina). Thickness of the layers 
greatly varies from species to species. In humans and other large mammals, the DA begins to 
differentiate itself from other great arteries of the heart in utero with intimal cushion 
formation (ICF)	  [45,	  46]. Antenatal ICF is characterized by lifting of the endothelium and 
expansion of sub-endothelial space. Hyaluronic acid synthesis and elastin fiber fragmentation 
facilitates the migration of smooth muscle cells into the sub-endothelial space. Antenatal ICF 
has not been reported in mice. This may be due to ICF not being necessary in mouse DA 
closure, or characteristics of mouse ICF are not easily identified by microscopy. In most 
large animals, only the outer 1/3 of the smooth muscle media is vascularized by vasa 
vasorum, and the inner smooth muscle layer receives nutrients and O2 via luminal blood flow 
[47]. In mice, the DA is not vascularized, and receives all its nutrients and O2 from luminal 
blood flow [48]. After DA constriction, ischemia plays a role in initiating permanent 
remodeling of the vessel into the ligamentum arteriosum [49, 50]. Currently, the exact cause 
of DA constriction and initiation of remodeling are unclear. There are numerous components 
known to play a role in DA closure such as gestational maturity, O2 tension, and 
prostaglandin levels (Table 1.1) [27, 51-53]. Many genes have been implicated in DA 
closure, however the exact role these genetic components play in DA maturation and closure 
and their possible interactions with each other remains unclear (See Table 1.2 for list of 
genes with known association with DA maturation/patency). Prostaglandins and their role in 
DA closure are briefly described in the following section. 
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Prostaglandins and the ductus arteriosus 
Prostanoids were implicated in the transition from fetal to adult circulation after an 
increase in incidence of premature in utero DA closure was reported in infants exposed to 
non-steroidal anti-inflammatory drugs (NSAIDs). Indomethacin, a potent NSAIDS, was 
routinely used to delay premature labor, however it was discovered that following maternal 
indomethacin treatment, the fetal DA often underwent closure, which can potentially lead to 
fetal pulmonary hypertension and other serious complications [54, 55]. These serendipitous 
discoveries lead to the use to indomethacin (and other NSAIDs) as pharmacological agent to 
induce DA closure in neonates that had not undergone proper DA closure after birth.  
NSAIDs inhibit cyclooxygenase (COX1 and COX2) activity, resulting in a decrease 
in all prostanoids. Prostanoids, a subclass of eicosanoids, are signaling molecules made by 
oxygenation of essential fatty acids, and include prostaglandins, prostacyclins, and 
thromboxanes (Figure 1.2). Prostanoids are metabolites of arachidonic acid (AA), and have 
numerous physiological roles including vascular tone, platelet aggregation, inflammation, 
and fever [56]. AA is a 20-carbon polyunsaturated fatty acid found in the phospholipid 
membrane of cells. COX, officially named prostaglandin-endoperoxide synthases, convert 
AA into prostaglandin endoperoxide (PGH2) through a two-step catalytic reaction involving 
dioxygenase activity and peroxidase activity. PGH2 is further metabolized by one of five 
enzymes: thromboxane synthase, prostacyclin synthase, or prostaglandin D, E, or F synthase.  
 Prostaglandin E2 synthase (PTGES) generates prostaglandin E2 (PGE2) from PGH2 by 
breaking the peroxide bond between C9 and C11. Prostaglandin D synthase and 
prostaglandin F synthase break the same peroxide bond, and the only principle difference 
between PGD, PGE, and PGF is the location of either a keto or alcohol group at C9 and C11. 
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PGE2 has wide range of physiological effects including vasodilation, fever induction, uterine 
contraction, bone resoprtion, and developmental control. Although PGE2 has a relative short 
biological half-life of about 30 seconds in circulation, PGE2 is tightly regulated by 
hydroxyprostaglandin dehydrogenase (HPGD) that breaks down PGE2 into biologically 
inactive 15-keto-PGE2 [57, 58].  
Of all the prostanoids that are downstream of COX inhibition by NSAIDs, it is PGE1/2 
that has a physiological role in DA patency. Exogenous neonatal infusion of PGE1/2 
maintains ductal patency in neonates. Maintaining ductal patency is crucial for infants that 
have congenital heart defects that rely on a shunting through the DA for survival such as 
transposition of the great arteries, pulmonary atresia/stenosis, tricuspid atresia/stenosis, 
coarctation of the aorta, hypoplastic left heart syndrome, critical aortic stenosis, and 
interrupted aortic arch. Patency of the DA will not sustain neonates with any of these serious 
heart defects, and surgical intervention is ultimately necessary. In the short term, a patent DA 
will allow for sufficient cardio-pulmonary circulation until surgical correction. 
PGE2 exerts its biological role through four distinct seven transmembrane domain G-
protein coupled receptors, the EP1-4 receptors [56]. In human DA, the EP4 receptor is 
expressed antenatal and neonatal by both the smooth muscle and endothelium [59]. In utero, 
the lamb and pig DA expresses EP2, EP3, and EP4 receptors, but only the EP2 receptor is 
present in the neonatal DA	  [60, 61]. The DA of fetal rabbits and rats only expresses the EP4 
receptor [62, 63]. In most species the EP4 receptor has been shown to be central to DA 
closure, but in some species the EP2 receptor may play a role in neonatal DA patency. The 
EP1 receptor has not been shown to play a role in DA maturation and closure in any species. 
In the lamb, EP3 receptor agonists have been reported to result in DA relaxation through a 
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potassium-ATP channel mechanism, but in the pig this effect was shown to be at best 
marginal compared to saline [60, 64]. Targeted disruption of all four PGE2 receptors in mice 
has confirmed that the EP4 receptor in mice, like most other species, is critical for DA 
maturation and closure, and the loss of EP1, EP2, or EP3 has no affect on DA closure [65-
68]. 
 
The EP4 receptor 
 The EP4 receptor is well conserved among amniotes (Figure 1.3). The human and 
mouse EP4 receptors share approximately 88% amino acid identity. In most species, the EP4 
locus consists of 3 exons; the first exon is often non-coding or codes for only the first few 
amino acids (<20 amino acids), the second exon codes for most of the seven transmembrane 
domains and the third exon codes for the cytosolic tail of the receptor. 
 The EP4 receptor has been implicated in an extremely wide range of physiological 
processes, and the molecular pathways activated by EP4 receptor signaling seem to be 
largely dependent on the cell type in which it is expressed. The EP4 receptor is Gs-protein 
coupled and stimulates adenylate cyclase upon ligand binding [56]. PGE2/EP4 signaling has 
a catabolic function in osteoarthritis by inhibiting proteoglycan synthesis and stimulates 
matrix degradation [69]. In human embryonic kidney cells, PGE2/EP4 signaling has been 
shown to cause transcriptional changes, through phosphatidylinositol 3-kinase, by 
stimulating early response growth factor expression [70]. Ex vivo preparations of human 
pulmonary veins are dilated by PGE2 through smooth muscle EP4 receptors, but PGE2 exerts 
a minimal vasodilatory affect on the pulmonary arteries, which lack smooth muscle EP4 
expression [71]. In vivo, the smooth muscle of most arterial vessels do not widely express the 
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EP4 receptors, but nevertheless the EP4 receptor has a vasodepressant affect when stimulated 
[72]. Additionally, a role in cell differentiation and expansion was recently reported for the 
EP4 receptor in T-cell helper cells [73].  
Fatal non-syndromic PDA in EP4 deficient mice was counter-intuitive because the 
loss of a dilatory receptor was not expected to result in the inability to close and remodel the 
arterial vessel	  [68]. It has been shown that EP4 receptor expression increases with gestational 
age, and this is consistent with the observation that the premature DA is insensitive to 
prostaglandin fluctuates. Selective activation of the EP4 receptors in the rat DA has also been 
implicated in ICF by stimulating hyaluronic synthase 2 (HAS2) [74]. However, the link 
between HAS2’s role in ICF in the mature DA, and the fatal patency of EP4 deficient 
animals is unclear, and perhaps circumstantial. Similarly, EP4 signaling has also been shown 
to stimulate cAMP-regulated guanine nucleotide exchange factor I (EPAC1), which plays a 
role in smooth muscle migration in ICF [75].  
In humans, ICF is crucial for successful DA closure, and does not occur in an 
immature DA. Visual inspection of the mouse EP4 deficient DA and wildtype DA reveals no 
gross morphological difference between the wildtype and EP4 deficient DA, and the 
presence or absence of ICF has not been reported in utero [68]. The lack of any apparent 
morphological difference between the full-term mouse DA destined to close and remodel 
(wildtype) and the mouse DA that is destined to remain patent (EP4 deficient) suggests that 
ICF is not the critical component of EP4 receptor signaling in DA maturation, and ICF is a 
by product of a EP4 induced DA maturation. Although the EP4 receptor is exerting a dilatory 
effect on the DA, as evidenced by neonatal PGE2 infusion, the role of the EP4 receptor in DA 
maturation is more complex than just vasodilation. 
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Char syndrome may provide some additional insight into the molecular causes of 
PDA. Char syndrome, an autosomal dominant disorder characterized by PDA, facial 
dysmorphism and hand abnormalities, is caused by mutations in the transcription factor AP-2 
beta (TFAP2β)[76]. An increase in PDA incidence in infants with other developmental 
defects is not necessarily relevant since a variety of other genetic developmental defects can 
cause secondary PDA in infants [77]. However, a novel frame-shift mutation in human 
TFAP2β, resulting in premature termination of the protein, has recently been implicated in 
non-syndromic PDA [78]. Expression of endothelin-1 (ET-1) in the DA is dependent on 
TFAP2β expression [79]. ET-1 has shown to be critical for the oxygen-induced initial 
constriction of the DA at birth, and ET-1 up-regulates EP4 receptor expression in other 
tissues [80, 81]. The relationship between the EP4 receptor and TFAP2β in the DA is 
circumstantial, but nevertheless the coincidence of non-syndromic PDA in humans with 
TFAP2β mutations and non-syndromic PDA in mice with EP4 receptor mutations should not 
be ignored. The loss of TFAP2β in mice does not reproduce the PDA seen in non-syndromic 
TFAP2β mutation in humans [82]. This discrepancy may be due to the differences between 
the mouse and human DA, the difference between TFAP2β null mouse locus and the 
TFAP2β truncated protein in humans, or TFAP2β having no relationship with DA 
maturation and closure. 
Ultimately, the exact molecular mechanism of DA maturation and closure is unclear, 
as is the role of the EP4 receptor in that maturation process. The chicken-and-the-egg circular 
argument can be made for many of the genetics components linked to DA maturation, does 
an event occur in a mature DA or does that event cause DA maturation. 
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Research presented in this dissertation 
 This dissertation aims at addressing the counter-intuitive phenomenon created by the 
persistent PDA (dilation) seen in mice deficient in EP4 (a dilatory receptor). Chapter 2 
analyzes the tissue-specific requirement of EP4 expression in the DA, and the transcriptional 
consequences of EP4 receptor expression in the DA. Chapter 3 examines prostaglandin-
independent DA maturation and closure that may explain the complex inheritance of PDA 
seen in larger animals (especially humans) that can not be explained by the disruption of a 
single pathway as seen in common inbred mouse strains. Concluding remarks in chapter 4 
summarize the work presented here and outline possible future direction to further elucidate 
the role of prostanoids in DA maturation and closure. 
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Figure 1.1. Diagram of basic (A-D) fetal circulation and (E-I) adult circulation in mammals. 
Foramen ovale (fo), ductus arteriosus (da), and ligamentum arteriosum (la) are labeled. (A) 
Inferior vena cava blood flow from the placenta is preferentially channeled through the 
foramen ovale into the right atrium. (B) Superior vena cava blood flow from the upper 
extremities is preferentially channeled to the right ventricle. (C) Right ventricular output is 
channeled through the ductus arteriosus to the descending aorta to the lower extremities and 
the placenta. (D) Left ventricular output provides systemic circulation to the upper 
extremities. (E-F) Venous blood flow from the inferior vena cava and superior vena cava 
mixes in the left atrium. (G) Right ventricular output through the pulmonary arteries enters 
the lungs for respiration. (H) Oxygenated blood returns from the lungs to the left side of the 
heart. (I) Left ventricular output provides systemic circulation for the entire body.  
 
           Fetal Circulation                                 Adult Circulation 
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Figure 1.2. Eicosanoid metabolism pathways with specific focus on prostaglandin 
metabolism.  
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Figure 1.3. Phylogenetic tree of the EP4 receptor. Phylogenetic tree constructed using 
protein sequence from 10 amniotes (dog, rabbit, rat, mouse, human, chimpanzee, armadillo, 
cow, lizard, and chicken) and zebra fish using Structure based Sequences Alignment Program 
(STRAP). The mouse, rat, human, chimpanzee, rabbit, and dog EP4 receptors share >88% 
amino acid identity, and the mouse and chicken EP4 receptors share >70% amino acid 
identity. 
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Table 1.1. Component of ductus arteriosus maturation and closure 
Component Summary Ref. 
Gestational 
Maturity 
Gestation age inverse related to incidence of PDA [83]  
Oxygen Initiation of pulmonary circulation results in increased plasma 
oxygen concentration in the DA triggering smooth muscle 
constriction; High altitude full-term births with increased 
incidence of PDA are treated by oxygen therapy 
[84] 
[42]  
Prostaglandins Neonatal PGE infusion maintains DA patency; inhibition of 
PGE production triggers DA closures 
[27] 
[85]  
Bradykinin Biphasic response to bradykinin by DA (relaxation at low 
levels and constriction at high levels) 
[86]  
Nitric Oxide NO induced DA relaxation/dilation [87]  
Carbon 
Monoxide 
DA relaxation/dilation with probable relationship to 
bradykinin and NO 
[88]  
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Table 1.2. Genes with a known relationship to ductus arteriosus maturation and/or closure.  
Genes Summary Ref. 
PGE2 receptors: 
EP2 & EP4 
Common inbred EP4 null mice succumb to fatal PDA. 
Some species utilize the EP2 receptor instead of EP4 
[68] 
[61]  
Cyclooxygenase 1 
& 2 
Localized PGE2 production in the DA plays role in DA 
closure, Increased incidence of PDA in COX-2 null mice 
[89]  
Hydroxy-
prostaglandin 
dehydrogenase 
PGE2 main catabolizing agent. HPGD null mice succumb 
to fatal PDA 
[90]  
Myocardin Transcription co-factor, neural crest smooth muscle loss 
results in fatal PDA in mice 
[91]  
Myosin, heavy 
polypeptide 11 
Delayed DA closure in MYH11 null mice [92]  
TFAP2B 
transcription factor 
Mutations in TFAP2B can result in non-syndromic PDA in 
humans 
[78]  
Rap guanine 
nucleotide 
exchange factor 3 
(EPAC1) 
Plays role in intimal cushion formation [75]  
IL-15 Might have an inhibitory effect on the physiologic vascular 
remodeling processes in closing the DA 
[93]  
Endothelin-1 Endothelin-1 receptor antagonism prevents DA constriction 
in rats 
[94]  
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Chapter 2 
Expression of the PGE2 EP4 receptor by smooth muscle cells is essential for closure of 
the ductus arteriosus at birth 
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ABSTRACT 
Background - The ductus arteriosus (DA) is a fetal shunt that directs right ventricular 
outflow away from pulmonary circulation and into the aorta. In many species including 
humans and mice, critical roles for prostaglandin E2 have been established in both 
maintaining the patency of the DA in utero and in its closure at birth. While studies in mice 
indicate that the EP4 receptor mediates these apparently incongruous actions of PGE2 in the 
DA, the pathways linked to the EP4 receptor triggering these dramatic events are not known. 
Moreover, since EP4 receptors are expressed in the endothelial and smooth muscle 
compartments of the DA, the cellular mechanisms underlying these functions are also 
undefined. 
Methods - To address these questions, we have generated mice in which loss of EP4 
expression is limited to either the smooth muscle or endothelial cells and have determined the 
consequences of these deletions on DA closure. In addition, to define gene expression 
patterns linked to EP4 receptor activation in the DA, we carried out genome wide expression 
analysis of vessels that developed in the presence or absence of PGE2/EP4 signaling. 
Results - These studies show that EP4 receptor expression in smooth muscle is absolutely 
required for DA closure; pups lacking EP4 receptors limited to smooth muscle die within 48 
hours of birth with a patent DA. In contrast, elimination of EP4 receptors from endothelial 
cells has no effect on the patency of the DA in utero or for closure and remodeling after 
birth. Analysis of DA from EP4-/- and wild type fetuses indicates that the PGE2/EP4 pathway 
alters the gene expression signature of the DA suggesting that in addition to its role in 
maintaining the patency of the vessel in utero, the EP4 pathway may also be important for 
developmental changes that allow the vessel to undergo remodeling at birth.  
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INTRODUCTION 
 
The ductus arteriosus (DA) is fetal arterial vessel that connects the pulmonary duct to 
the aorta. It thus allows the majority of right ventricular output to be directed past the fluid-
filled fetal lungs towards the descending aorta and placental circulatory system where 
oxygenation takes place. Rapid closure of the vessel occurs in most mammalian neonates 
within 48 hours of birth. In humans failure of the vessel to undergo closure and remodeling 
can lead to pulmonary hypertension later in life. Closure of the vessel is believed to occur in 
two steps, with the initial constriction of the vessel largely triggered by an increase in arterial 
oxygen tension (as ventilation of the lung is initiated) and by a precipitous drop in PGE2 
levels at birth. Remodeling of the vessels is initiated with the lifting of the endothelium from 
the internal elastic lamina, fragmentation of the elastin and migration of smooth muscle cells 
into the sub-endothelial space [1]. This is followed by dramatic structural changes that result 
in the eventual transformation of the vessel into the ligamentum arteriosus. 
The patency of the DA, both in utero and immediately after birth is sensitive to 
NSAIDs drugs such as indomethacin which block production of all prostaglandins and 
thromboxane by inhibiting cyclooxygenase (COX) activity. The cyclooxygenase isozymes 
convert arachidonic acid into prostaglandin endoperoxide (PGH2), a rate-limiting step in all-
downstream prostaglandin, prostacyclin, and thromboxane synthesis [2]. Exposure of the 
fetus to indomethacin can result in DA closure in utero [3], and neonatal indomethacin 
treatment can often bring about the closure of a PDA in a neonate [4]. Furthermore, 
prostaglandins, including PGE2 can relax the pre-constricted ductus in vitro [5] and infusion 
of PGE2 maintains the patency of the vessel after birth [6]. Together these experimental and 
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clinical findings supported a model in which the DA was regarded as having intrinsic tone 
with the patency of the fetal vessel in utero dependent on the dilatory actions of 
prostaglandins; PGE2 and perhaps prostacyclin [7]. A dramatic drop in circulating 
prostaglandin levels occurs at birth because of loss of the prostanoid rich placental capillary 
beds and because of the redirection of the right ventricular output to the pulmonary 
circulation where high levels of the PGE2 catabolizing enzyme HPGD are expressed. Loss of 
this vasodilatory mediator allows the intrinsic tone of the vessel to close the fetal shunt. The 
importance of the rapid decrease in PGE2 levels at birth in closure of the DA is supported by 
the finding that mice lacking HPGD die in the perinatal period with PDA and a high 
incidence of patent ductus arteriosus (PDA) in families carrying a mutant allele of this gene 
[8, 9].  
This model in which PGE2 counteracts the normal tone of this vessel is consistent 
with the known potent dilatory action of PGE2 in most vascular beds. This dilatory action is 
endothelial-dependent and believed to be dependent largely on the ability of PGE2 to 
stimulate the production of NO by eNOS present in endothelial cells. NO stimulates soluble 
guanylate cyclase allowing accumulation of cGMP in the smooth muscle cells. The dilatory 
actions of PGE2 have been attributed primarily to two of the four PGE2 receptors, EP2 and 
EP4 receptors [5]. However, when examined more carefully, the phenotype of the EP4-
deficient mice suggests a more complex role for prostaglandin in the physiology of this 
vessel, including the possible role for this receptor on smooth muscle cells. Here we describe 
experiments designed to identify the cell types critical to the function of the EP4 receptor in 
both prenatal and perinatal physiology of this vessel and in ensuring normal closure of this 
vessel at birth. 
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METHODS 
In situ hybridization 
The Ptger4 specific cDNA probe was synthesized by reverse transcription and PCR 
amplification using primers Ptger4-1F (5’-GTTTGGCTGATATAACTGGTTAAT-3’) and 
Ptger4-2R (5’-ACCTGGTGCTTCATCGACTGGACC-3") and total thymus RNA as a 
template. The PCR fragment was cloned using a TA cloning kit (In Vitrogen) and S35-labeled 
probes prepared using a commercially available kit (Ambion). The DA was embedded in 
OCT compound, transverse sections 8 to 10µm in thickness were prepared, and in situ 
hybridization carried out as described. 
 
Generation of a loxP-flanked conditional null Ptger4 allele 
The targeting plasmid was assembled using the vector pXenaFL2, which contains a 
neomycin gene flanked by loxP and Frt sites, driven by a PGK promoter and a PGK driven 
Tk gene that makes it possible to select against cells in which targeting plasmids have 
randomly integrated into the mouse genome by growth in ganciclovir. Fragments of DNA 
corresponding to various regions of the Ptger4 gene were amplified by PCR from DNA 
prepared from the ES cell line TC1 [10]. A 4912 bp fragment of DNA corresponding to 
intron 2 of EP4, beginning just 94 bp from the end of exon 2, was cloned 3’ of the PGKneo 
gene in pXenaFL2, generating pXenaFL2-EP4-3’. A second segment of the EP4 gene, 
including the last 154 bp of intron 1, exon 2 and the first 94 bp of intron 2 was amplified and 
cloned just 3’ of the loxP site in pNEBlox. pNEBloxP was derived by insertion of a loxP 
sequence between the Pst1 and HindIII sites pNEB193. This EP4 fragment together with the 
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loxP site was then excised from pNEBloxP and cloned 5’ of the neo gene in pXenaFL2-EP4-
3’ generating pXenaFL2-EP4-3’/M. A third fragment of the EP4 gene, containing 
approximately 5kb of 5’flanking DNA, exon 1 and the 5’ portion of intron 1 was amplified 
by PCR and cloned 5’ of the pNEBloxP derived loxP site present in pXenaFL2-EP4-3’/M.  
The Not 1 linearized targeting plasmid was electroporated into TC1 a 129S6 derived 
ES cell line and transfected cells selected by growth in G418 and ganciclovir. ES colonies 
were individually expanded, DNA prepared and subjected to Southern blot analysis, using a 
751 bp probe located just 3’ of the region of Ptger4 DNA included in the targeting vector, to 
identify clones in which the plasmid integrated into the mouse genome by homologous 
recombination. These colonies were further screened by Southern analysis using a probe 
corresponding to exon 2, to identify those clones in which the recombination event also 
resulted in introduction of the loxP site into intron 1. 80 G418 ganciclovir resistant colonies 
were analyzed: of these 7 had integrated the plasmid by homologous recombination, and of 
these 3 had the loxP site present in intron 1 of Ptger4. These ES cell were used to generate 
chimeras capable of transmitting the modified Ptger4 allele to their offspring. By breeding 
the chimeras with 129S6 females, the conditional null allele was maintained on the 129S6 
genetic background. To remove the neomycin gene from intron 2, but leave intact exon 2 
flanked by loxP sites, mice were crossed with a 129S4 line that expresses a variant of the 
Saccharomyces cerevisiae FLP1 recombinase gene under the direction of the 
Gt(ROSA)26Sor promoter [11]. Mice carrying the conditional Ptger4 allele were identified by 
PCR. 
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Transgenic Mouse lines 
All protocols were approved by the Institutional Animal Care and Use Committee at 
the University of North Carolina. The generation of mice lacking EP4 and EP2 receptors is 
described elsewhere [12, 13]. The Ptger4+/- mice were maintained on a 129S6 background. 
C57BL/6 Ptger2+/- mice were crossed for 4 generations to 129S6 before use. All recombinase 
mouse lines were obtained from Jackson Laboratories. 129S4/SvJaeSor-
Gt(ROSA)26Sortm1(FLP1)Dym/J (Stock # 003946) were maintained on a 129S6 
background [11]. B6.Cg-Tg(Tek-cre)129Flv/J lines (Stock #004128), referred to here as Tek-
cre mice, were crossed for seven generations to 129S6 prior to intercross with mice carrying 
the conditional null allele [14]. STOCK Tg(Tagln-cre)1Her/J (Stock #004746), referred to 
here as Tagln-cre, were crossed for nine generations to 129S6 mice prior to intercross with 
mice carrying the conditional null allele [15]. STOCK Tg(Wnt1-cre)11Rth Tg(Wnt1-
GAL4)11Rth/J (Stock #003829), referred to here as Wnt1-cre mice, were crossed for two 
generations to 129S6 mice prior to intercross with mice carrying the conditional null allele 
[16]. B6.C-Tg(CMV-cre)1Cgn/J (Stock # 006054), referred to as CMV-cre mice in this 
manuscripts, was maintained on a BALB/C genetic background [17]. In all cases the 
presence of the Cre recombinase transgene was identified by using primers specific for cre 
recombinase coding sequence (upper 5’-TTACCGGTCGATGCAACGAGT-3’; lower 5’- 
TTCCATGAGTGAACGAACCTGG-3’).  
 
Quantitative RT-PCR 
Total RNA was isolated from tissues using Qiagen RNeasy Minikit or Microkit. 4-8 
ductus arteriosi of identical genotype were pooled prior to extraction of RNA. Reverse 
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transcription of RNA to cDNA for quantitative RT-PCR was performed using a high-
capacity cDNA archive kit (Applied Biosystems) according to the manufacturer’s 
instructions. Primers and probes were purchased from Applied Biosystems. All reactions 
were performed with TaqMan PCR Universal Master Mix (Applied Biosystems) using the 
Applied Biosystems 7900 HT Fast Real-Time PCR System. Reactions were performed in 
duplicate in a 20µl final volume reaction using 10ng of cDNA. Expression levels of genes of 
interest were normalized to either β-2 microglobulin (B2M) or GAPDH levels. Data were 
analyzed using the comparative CT method as described by Applied Biosystems. 
 
Full term DA RNA for Expression Profile 
DAs were isolated from 18.5 day full-term fetuses and individually stored at -80C 
until the genotype of the embryos was determined. RNA, from pooled samples of 8 
genetically identical vessels, was isolated using Qiagen RNeasy Micro Kit as per 
manufacture’s tissue isolation protocol. RNA quality was accessed with Agilent 
Technologies’ RNA 6000 Nano Chips. Samples with distinct 18s and 28s rRNA peaks and 
no visible degradation or genomic DNA contamination were used for Illumina Beadchip 
microarray analysis. 
 
Genome Wide Expression Profile 
Illumina Beadchip microarray hybridization was done as per manufacture’s protocol 
(brief described below) by Expression Analysis (Durham, NC). The Illumina Direct 
Hybridization assay begins with using the Illumina® Total Prep RNA Amplification Kit for 
making biotin-labeled cRNA from the poly-adenylated portion of eukaryotic total RNA.  The 
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total RNA is reverse transcribed into single-stranded cDNA. The single stranded cDNA is 
converted to double stranded cDNA, which is followed by column purification of the double 
stranded cDNA. Purified double stranded cDNA is converted to biotin-labeled cRNA during 
an in vitro transcription reaction. The biotin-labeled cRNA is column purified, and then 
quantitated using OD260 measurements.  1.5 ug biotin-labeled cRNA is mixed with a 
hybridization buffer and hybridized to a Sentrix Array Matrix.  Gene-specific probes on the 
Array hybridize the biotin-labeled cRNA.   After hybridization, non-hybridized material is 
washed away.  Following the wash step, the Array is washed with a blocking solution.  Next, 
a SA-Cy3 stain solution is washed over the Array, allowing the biotin-labeled cRNA to bind 
the SA-Cy3. Excess stain is then washed away and the Array is allowed to dry. The SA-Cy3 
signal is then detected by the Illumina BeadArray reader.  
A total of 8 microarrays were analyzed; four wildtype DA and four EP4 deficient DA. 
Illumiuna BeadStudio (v1.5) was used to normalize the data with cubic-spline normalization. 
Differential expression lists were determined based on >1.25 fold change p-value < 0.05.  
 
Statistical Analysis 
 Statistical analysis of quantitative real-time RT-PCR was performed using Prism 4 
(GraphPad Software). Comparisons of the distributions were made by Mann Whitney U test 
unless otherwise noted. Data are shown as median ± S.E.M. Differences with p < 0.05 were 
considered statistically significant and denoted with a * unless otherwise noted. Test of 
proportions was used to calculate statistical significance of survival data.  
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RESULT 
 
Expression of the EP4 receptor in the ductus 
Consistent with previous studies, analysis of transverse sections through the ductus 
with Ptger4 specific probes showed high levels of expression of Ptger4 in the vessel, with an 
intense signal in the layers containing the smooth muscle (Figure 2.1). Ptger4 expression in 
the vasculature is generally highest in the endothelial cells. Therefore, to examine this point 
further longitudinal sections were prepared from the ductus. This again showed high 
expression of Ptger4 in the layers containing the smooth muscle cells of the DA. However, it 
also reveals an abrupt change in expression at the junction between the smooth muscle of the 
DA and the aorta, with little to no expression in Ptger4 in smooth muscle cells of this vessel. 
This was confirmed by examination of cross section of the aorta. Similarly, little expression 
of Ptger4 was detected in the smooth muscle pulmonary duct. In contrast expression of 
Ptger4 by endothelia cells was apparent in all vessels. Thus in the DA unlike other greater 
vessels Ptger4 appears to be expressed by both the endothelial cells and the smooth muscle 
cells.  
 To quantify the difference in expression of EP4 in these muscular arteries, RNA was 
prepared from the DA of a full term fetus, the adult aortic arch, and adult abdominal aorta 
and the abundance of Ptger4 transcripts was determined by quantitative real-time RT-PCR. 
Ptger4 transcripts were six time more abundant in the RNA prepared from the DA than in 
samples prepared from either the abdominal aorta and aortic arch. 
 
Generation of the mice carrying a conditional null Ptger4 allele  
 43 
To distinguish between the functions of the EP4 receptor in smooth muscle cells and 
endothelial cells we first generated a mouse line carrying a conditional null allele (Figure 
2.2). In this allele exon2 is flanked by loxP sites and therefore is predicted to be excised in 
cells expressing Cre recombinase [18]. This exon was chosen because it encodes the majority 
of EP4 including the first six transmembrane, intra and extra cellular domains as well as a 
portion of the seventh transmembrane domain. Targeted ES cells were identified by Southern 
analysis and then subjected to further analyses to determine whether the recombination event 
resulted in the introduction of the loxP site into intron 1. These targeted ES cells were 
introduced into C57BL/6 blastocysts and the resulting chimeras bred with 129S6 mice to 
establish the Ptger4flox-neo mouse line. To verify that the loxP sites are functional and confirm 
that loss of the DNA flanked by the sites would generate a null allele these animals were 
mated to a transgenic line that ubiquitously expresses Cre. In these animals expression of Cre 
should result in recombination between loxP sites and thus the loss of exon2 and generation 
of a null Ptger4 locus. As expected when these animals were intercrossed with mice 
heterozygous for the null Ptger4 allele, 25% of the mice died with a PDA (data not shown).  
Mice heterozygous for the modified allele were intercrossed and pups homozygous 
for the Ptger4flox-neo allele identified. Analysis of lines generated both by our lab and others 
indicate that the presence of a neomycin-resistant gene in an intron can interfere with gene 
expression [19]. We therefore also bred the Ptger4flox-neo/+ mice to mice expressing FLP 
recombinase in their germline. Expression of FLP recombinase in mice carrying the Ptger4 
flox-neo/+ is expected to result in excision of the neomycin gene from intron 2, leaving a Ptger4 
allele, Ptger4flox, which differs from the wild type locus only in the presence of loxP sites and 
DNA linkers sequences in intron 1 and 2 (less than 400 exogenous bp). PCR and Southern 
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Blot confirmed the loss of the neomycin gene. Expression of Ptger4 in mice homozygous for 
either the Ptger4flox or the Ptger4flox-neo allele was then determined. RNA was prepared from a 
number of tissues including the DA and the abundance of Ptger4 transcripts relative to those 
present in wild type animals determined by quantitative real-time RT-PCR. As can be seen in 
Figure 2.3 the expression of the EP4 receptor by the floxed locus did not differ significantly 
from that of the wild type locus in any of the arteries examined. In contrast, expression of 
EP4 was significantly lower in tissue isolated from animals homozygous for the Ptger4flox-neo 
allele indicating that the introduction of the neomycin gene had resulted in the generation of 
Ptger4 hypomorph. Closure of the DA in the perinatal period was normal in the homozygous 
Ptger4flox pups and also in mice homozygous for the Ptger4flox-neo allele. Given that mice 
heterozygous for the null allele undergo normal remodeling of the DA and that the level of 
expression in the hypomorphs is approximately 30-50% of that seen in the wild type animals, 
this is perhaps not surprising.  
  
Endothelial cell-specific loss of EP4 and DA patency 
In situ analysis (Figure 2.1) shows expression of EP4 receptor by endothelial cells, 
and many studies indicate that PGE2 can modulate vascular tone through its action on this 
cell type. It was therefore of interest to determine whether this expression also played a role 
in either maintaining the patency of this vessel in utero or in the closure of the vessel after 
birth. Ptger4flox/flox mice were intercrossed with mice heterozygous for the Ptger4 null allele 
that also carry a Cre transgene controlled by the endothelial specific promoter of the Tek 
gene.  
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A similar cross was generated using Ptger4flox-neo/flox-neo mice. We reasoned that the 
lower expression of the gene in the hypomorph would increase our ability to observe a 
physiological impact of loss of expression of the EP4 receptor by endothelial cells. No 
difference in the survival of embryos carrying the flox/null or flox-neo/null alleles and the 
cre transgene was observed (Table 2.1). Furthermore these pups survived the neonatal period 
and necropsy of weanlings revealed the formation of the ligamentum arteriosus. To verify 
that endothelial specific loss of Ptger4 expression had occurred in these mice we examined 
expression of the EP4 receptor in the aortic arch and abdominal aorta (Figure 2.4), as in these 
vessels, in situ analysis indicated that expression was limited to this cell type. EP4 expression 
was significantly reduced in both tissues.  
Endothelial cells express a second Gs-coupled PGE2 receptor, the EP2 receptor. It is 
therefore possible that this receptor plays a redundant role in this cell type compensating for 
loss of EP4. To rule out this possibility we examined the impact of endothelial specific loss 
of EP4 on an EP2-/- genetic background. Pups lacking expression of EP2 and EP4 on 
endothelial cells were present in litters at expected frequency. This indicates that loss of these 
Gs-coupled dilatory PGE2 receptors is not required for the maintenance of fetal blood flow. 
The ductus of these animals retained their dependence on PGE2 for patency: treatment of the 
dams with NSAID resulted in closure of the DAs of both wild type and EP2-/- EP4flox/- Tek-
cre pups. 
 
Smooth muscle-specific loss of EP4 receptor expression 
As seen in Figure 2.1, the media of the ductus expresses high levels of EP4, likely 
reflecting expression of this receptor by smooth muscle cells. We therefore next intercross 
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the mice carrying both the flox and the flox-neo Ptger4 alleles with mice expressing Cre 
under the control of the Tagln(Sm22) promoter. This promoter directs Cre expression in both 
vascular and non-vascular smooth muscle. Expression analysis indicated that Tagln is 
expressed in the DA (data not shown). We therefore expected mice expressing the Tagln-cre 
and the flox alleles would lack expression of the receptor in smooth muscle cells only, 
allowing us to isolate the function of EP4 receptors on these cells in DA closure. As can be 
seen in Table 2.1, all Ptger4flox-neo/- mice expressing the Tagln-cre die in the perinatal period 
with a PDA indistinguishable from that observed in mice homozygous for the null allele. The 
loss of EP4 in smooth muscle cells was confirmed by real-time RT-PCR analysis of RNA 
isolated from the DA of wild type mice, Ptger4flox/- mice, Ptger4flox/- Tagln-cre mice, and 
Ptger4-/- pups (Figure 2.4). As expected, no expression of the Ptger4 was detected in the 
Ptger4-/- pups. Low but significant expression of the gene was detected in DA of the 
Ptger4flox/- Tagln-cre mice. This is consistent with the undisturbed expression of the receptor 
on endothelial cells in the Tagln-cre mice. However, not surprising, given muscularity of this 
vessel, the expression of EP4 by the Tagln-cre Ptger4flox/- mice was dramatically lower than 
that observed in the DA from wild type animals. To determine whether the loss of expression 
of the receptor on the smooth muscle altered the response of the vessel to loss of PGE2, dams 
were treated with indomethacin and the patency of the vessel scored in 18.5-day fetuses. The 
ducti of full term fetuses lacking expression of EP4 on smooth muscle cells remained patent 
in the absence of PGE2, while as expected the closure was seen in littermates with normal 
EP4 expression.  
 
Loss of EP4 in Neural crest derived smooth muscle cells 
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Tagln is expected to drive expression of Cre in all smooth muscle cells, not only those of the 
DA. This raises the possibility the PDA observed in the Tagln-cre Ptger4flox/- mice reflects 
the combined effect of the loss of expression of this gene on multiple smooth muscle 
populations. To address this concern we generated mice in which loss of EP4 expression was 
limited to neural crest derived cell, the primary embryonic origin of the smooth muscle cells 
of the DA and other great arteries of the heart [20]. Mice homozygous for either the flox or 
flox-neo Ptger4 allele were crossed with Ptger4+/- mice carrying the Cre transgene driven by 
the Wnt-1 promoter. This limits loss of EP4 expression to all smooth muscle cells of the DA 
and a portion of the smooth muscle cells of the other greater arteries. Neural crest-EP4 
receptor deficient mice succumb to cardiovascular failure as a result of persistent patency of 
the DA after birth, identical to that seen in the smooth muscle EP4-deficient mice and in  
EP4-/- animals (Table 2.1).  
 
Identification of PGE2/EP4 dependant gene expression in the DA.  
To gain a mechanistic understanding to the contribution of EP4 receptor on the smooth 
muscle cells to both closure of the vessel at birth and to the dilatory actions of PGE2 in utero 
we carried out expression analysis of DA isolated from full term Ptger4-/- and Ptger4+/+ 
fetuses. We reasoned that differences in the expression of genes in these DA would identify 
pathways those activities were either directly or indirectly altered by exposure of the DA to 
PGE2 and activation of the EP4 pathway during embryo development. While no 
morphological differences are observed between the DA of wildtype and EP4-/- fetus, we 
were surprised to find that gene expression analysis revealed 282 transcripts with statistically 
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significant differential expression (p < 0.05, fold change > 1.25). See Table 2.2 and Table 
2.3, for a list of all 282 differential expressed transcripts.  
 Pathway analysis on the 282 differentially expressed genes was done using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) at National 
Institute of Allergy and Infectious Diseases (NIAID), NIH [21, 22]. Gene Functional 
Classification clustered the genes enriched in the wildtype DA into 4 clusters (enrichment 
scores >1.0). A cluster of transmembrane protein (enrichment score: 1.79) and proteases 
(enrichment score: 1.63) without any specific relation to prostanoids or arterial vessels. 
However, the other two clusters enriched in the wildtype DA are troponin-myosin related 
(enrichment score: 3.6) and tubulin-related (enrichment score: 1.1). Gene Functional 
Classification clustered the genes enriched in the EP4 deficient DA into 3 clusters 
(enrichment score >1.0): cytochrome-related cluster (enrichment score 1.82), atapase/ion 
transport cluster (enrichment score: 1.09), and mast cell related cluster (enrichment score: 
1.01). See Table 2.4 for list of genes in each cluster.   
Additional analysis of functional clusters was done with Ingenuity Pathway Analysis 
(v7.5). Multiple genes in the clusters enriched in the wildtype DA are expected to be 
sensitive to myocardin/serum response factors. Expression of both myocardin and one of its 
differentially expressed targets (myosin heavy chain 11) were analyzed in the full term DA 
from Ptger4+/+ and Ptger4-/- fetuses. Both myocardin and myosin heavy chain 11 levels were 
significantly decreased in the Ptger4-/- DA compared to wildtype DA (Figure 2.5). To 
confirm the decrease was not due to a general decrease in muscularity of the Ptger4-/- DA, 
myosin light chain 7 (MYL7) was used as a control. MYL7 is expressed in cardiac smooth 
muscle and the aorta but expression patterns of MYL7 have not been shown to be 
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myocardin/SRF dependent. Consistent with the hypothesis, Myl7 transcript levels did not 
differ in Ptger4+/+ and Ptger4-/- DA. 
  
 
DISCUSSION 
 
Our studies show that the EP4 receptor is highly expressed by cells located in the 
media of the DA. In fact, transverse sections through the vessel indicate that the EP4 
expression in this vessel serves as a marker for this great artery, distinguishing it from the 
adjoining pulmonary truck and aorta. Using mouse lines in which the expression of EP4 is 
limited to either the smooth muscle cells or endothelial cells, we provide evidence supporting 
both a dilatory and metabolic role for this receptor in this vessel, with both of these actions 
mediated through the EP4 receptor present on the smooth muscle cells.  
 The expression of EP4 by endothelial cells including those of the DA is consistent 
with a model in which activation of EP4 receptors leads to the production of dilatory 
mediators that act on the underlying smooth muscle cells to maintain patency of the vessel 
(Figure 2.6). However, while such a model accounts for the ability of PGE2 to maintain the 
patency of the DA in utero and after birth, it is not consistent with our finding that fetal 
expression of the EP4 receptor by endothelial cells is not required for the normal 
development. Pups lacking endothelial EP4 expression are born at expected ratios, and 
normal closure after birth indicates that the vessel has matured and is capable of constriction 
and remodeling after birth. In addition, maternal exposure to indomethacin results in DA 
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constriction in these fetuses, despite the fact that the endothelium of the ductus of these 
animals would be insensitive to changes in circulating levels of PGE2.  
 PGE2 can mediate relaxation of other smooth muscle through Gs couple receptors. 
For example, relaxation of airway smooth muscle is mediated through the Gs coupled EP2 
receptor [23]. The observation that a rapid decrease in PGE2 levels can lead to rapid 
constriction of the DA, either at birth or in response to maternal indomethacin treatment, 
suggests that PGE2 does act, at least in part, though similar dilatory pathways in the DA. 
However, if this represented the only function of smooth muscle EP4 receptor pathways, 
premature closure of the vessel in utero would be expected in the Tagln-cre Ptger4flox/- 
animals.  
 Taken together, the pharmacological and genetic studies suggest that a more complex 
model is required to describe the contribution of the EP4 receptor to the physiology of this 
vessel. PGE2 is known to promote growth of many cell types. PGE2 enhanced proliferation of 
murine aortic smooth muscle cells [24]. PGE2 has also been shown to stimulate vascular 
endothelial growth factors in human airway smooth muscle cells [25]. In cardiac myocytes 
EP4 is linked to hypertrophy through the p42/44 MAPK pathway [26]. In one study, EP4 was 
reported to induce hyaluronic acid production in DA explants from rats [27]. These 
observations raise the possibility that, in addition to its function in maintaining the patency of 
the DA, PGE2 through the EP4 receptor is essential for the maturation of the vessel, inducing 
the expression of genes essential for the closure and remodeling of the vessel at birth. 
The demonstration here that the absence of EP4 receptors dramatically alters the 
expression signature of the DA supports such a model. One gene of particular interest that is 
differentially expressed in the Ptger4-/- and Ptger4+/+ ducti is Myh11, smooth muscle myosin. 
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Mutations in MYH11 have been linked to hereditary PDA, and the loss of MYH11 in mice 
results in delayed closure of the DA [28, 29]. Expression of MYH11 and a number of other 
smooth muscle proteins that contribute to the contractility of the DA is regulated by 
myocardin. Myocardin, a coactivator for serum response factor (SRF), is a widely expressed 
transcription factor essential for the normal differentiation of cardiomyocytes and smooth 
muscle cells [30, 31]. Interestingly, although the difference in the expression of this 
transcription factor in Ptger4-/- and Ptger4+/+ tissue did not achieve statistical significance in 
microarray analysis, quantitative PCR analysis indicated significantly lower levels of 
myocardin mRNA in the Ptger4-/- ductus. A role for this pathway in the maturation and 
closure of the DA is supported by previous reports of PDA in pups lacking expression of 
myocardin in neural crest derived smooth muscle cells [20]. This raised the possibility that 
the PGE2/EP4 pathways may be required for maximal induction of myocardin and thus for 
the optimal development of the contractile phenotype of the DA.  
The restriction of EP4 expression in the fetus to the DA smooth muscle would 
provide a means of limiting the growth promoting actions of PGE2 to this vessel. Exposure of 
the DA to increasingly high levels of PGE2 would trigger the synthesis of contractile 
proteins, together with other genes required for eventual remodeling of the vessel, increasing 
the tone of the vessel in late gestation. This role for PGE2/EP4 is consistent with the PDA 
observed in the mice lacking EP4 receptor and with the PDA we report here in the mice 
lacking the expression of the EP4 receptor in the smooth muscle. The ability of EP4 to 
modulate the expression of genes in the DA supports a model in which this receptor carries 
out two function in the DA; it functions to maintain the patency of the vessel by inhibiting 
smooth muscle contraction and it induces the expression of genes that increase the 
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contractility of the vessels, and perhaps also, genes necessary for the remodeling of the vessel 
after birth.  
 The ductus is unique among the great arteries in its expression of extremely high 
levels of the prostaglandin receptor EP4. Our studies suggest that this expression pattern 
evolved to allow for rapid alteration of blood flow at birth, changes required for transition 
from placental to pulmonary oxygenation of blood. Expression of high levels of EP4 on DA 
smooth muscle cells provides a means by which the contractile properties of this vessel could 
be increased independent of other arteries. Importantly, by utilizing the EP4 receptor, a Gs 
protein coupled receptor for this task; the increase in the contractile properties of the DA 
could balance the concurrent increases in dilatory signaling. Furthermore, by linking the 
maturation and patency of the DA to EP4 a connection was established between the 
physiology of this vessel and the maturation of the fetus. PGE2 levels peak late in gestation, 
but drop precipitously at birth, depriving the DA of the EP4 dilatory pathway and allowing 
the contractile properties to act unopposed contributing to closure of the fetal shunt. 
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Figure 2.1. Expression of Ptger4 in the ductus arteriosus. (A, B) Transverse sections of DA 
from the 18.5 day mouse fetus; (C, D) longitudinal sections of DA from neonate; (E, F) 
transverse sections of neonatal aorta; (G, H) transverse section of neonatal pulmonary trunk; 
sections were hybridized with 35S labeled Ptger4 antisense probe (A,C,E,G) or Ptger4 sense 
probe (B,C, F,H). Scale bar is 150µM. I) Ptger4 transcript levels in abdominal aorta, aortic 
arch, and DA as measured by quantitative real-time RT-PCR 
I 
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Figure 2.2. Schematic depicting the generation of a conditional null EP4 allele. A) The 
structure of, the endogenous EP4 locus, the targeting plasmid, and the EP4 allele generated 
by homologous recombination of the plasmid with the wild type locus and the expected 
structures of these alleles in cells expressing either FLP or Cre recombinase, is shown.  
Restriction enzymes sites and probes used in identification of cells carrying a correctly 
targeted allele are indicated.  The loxP and FRT sites are represented by filled and open 
triangles, respectively.  EcoRI is abbreviated as RI.  Filled, numbered boxes represent exons. 
B and C Identification of ES cell clones in which the targeting plasmid integrated by 
homologous recombination and in which this recombination event results in introduction of 
the loxP site into intron 1.  Integration of the targeting plasmid by homologous 
recombination results in the introduction of an additional ScaI site generating a novel 6.6 kb 
Sca1 DNA fragment detectable by a probe located just 3’ of the segment of the EP4 locus 
used to assemble the targeting construct.  While only the Sca1 fragment corresponding to the 
endogenous EP4 locus is present in DNA shown in lane 1, the presents of a 9.8 and 6.6 kb 
fragment in lane 2 indicates that in this cell line one of the two EP4 alleles has undergone 
homologous recombination with the targeting plasmid. Recombination between the targeting 
plasmid and the endogenous locus can occur at any point along regions of homology.  To 
identify those ES cells in which recombination occurred 5’ to the loxP site in intron 1, a 
second screen was carried out on all targeted ES cells.  The presents of an EcoRI site in the 
linker DNA of the loxP site is expected to reduce the size of the EcoR1 fragment detected by 
a probe corresponding to exon 2.  This probe detects an endogenous fragment of 5.5 kb and 
either a 7.8 kb or 3.7 kb in targeted ES cells lines, with the later fragment indicative of a 
crossover event 5’ to the location of the loxP site in intron 1.  Although the cell line 
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corresponding to the DNA analyzed in panel C lane 1 carries a targeted EP4 allele, this line 
lacks the loxP site in intron 1. In contrast, the presence of the 3.7 kb EcoR1 fragment in lane 
three indicates that in this line intron 2 is flanked by loxP sites.  The DNA shown in lane 2 
was prepared from an untargeted ES cell line. D.  Excision of the floxed EP4 exon 2 in cells 
expressing Cre recombinase was verified by preparing DNA from mice generated by 
intercross of EP4flox mice with mice expressing Cre recombinase in their germline. The 
presence of a 8.9 kb Sca1 fragment detected by the 3’ probe in DNA shown in lane 2 is 
consistent with Cre-mediated excision of exon 2 from the targeted allele.  The Sca1 fragment 
generated from the EP4floxP allele is ~300bp larger than the wild type (WT) allele, due to the 
presence of the loxP sites and linker sequences. This small difference in size prevents 
resolution of these two alleles on Southern analysis with Sca1.     
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Figure 2.3. Quantitative RT-PCR demonstrating relative expression of the Ptger4 receptor in 
mice homozygous for the conditional null Ptger4 alleles. RNA was prepared from the adult 
(A) Lung (n=5), (B) aortic arch (n=4), and (C) abdominal aorta (n=5), and from the (D) full 
term (18.5E) DA (n=5) of animals with the indicated genotype. Differential expression from 
wildtype was determined by Mann-Whitney U test: * p < 0.05 
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Figure 2.4. Ptger4 receptor expression in endothelial cells and smooth muscle cells. (A) 
Aortic arch (n=8) and (B) abdominal aorta (n=8) RNA was examined from adult animals 
heterozygous for Ptger4 null, Ptger4flox, and genetically identical littermates expressing Tek-
cre. (C) Adult kidney (n=5) from mice homozygous for the Ptger4flox-neo and mice 
heterozygous for Ptger4 null, Ptger4flox-neo expressing Tek-cre (D) DA (n=5 pools) and (E) 
fetal kidneys (n=6) RNA was examined from 18.5 day fetuses heterozygous for the Ptger4 
null, Ptger4flox, genetically identical embryos expressing Tagln-cre, and Ptger4 null fetuses. 
Differential expression determined by Mann-Whitney U test: * p < 0.05 
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Figure 2.5. Quantitative real-time RT-PCR evaluation of Myocd, Myh11, and Myl7 in the 
ductus arteriosus of wildtype and EP4 deficient animals. RNA was prepared from full term 
(18.5E) DA (n=8 pools, 4 DA/pool) of animals with the indicated genotype. * p < 0.05 
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Figure 2.6. Models for the role of EP4 in the maturation and closure of the ductus arteriosus. 
A) DA has intrinsic tone that is counteracted by PGE2 through endothelial EP4 receptors. 
This model predicts premature closure in EP4 deficient mice. B) No EP4 dependent dilatory 
signal is required to maintain patency. PGE2/EP4 is responsible for the maturation of the DA, 
resulting in increase tone, which is required for closure at birth. However, this model is not 
consistent with the ability of indomethacin to rescue HPGD-/- mice. If PGE2 had no dilatory 
function, the loss of PGE2 would not be expected to cause closure. C) In this model, PGE2 
has two roles in the physiology of the DA. First through the smooth muscle EP4 receptors, 
PGE2 provides a metabolic signal stimulating maturation. At the same time, PGE2, through a 
dilatory signal via the endothelium, counteracts increasing tone of the DA. However, this 
model would predict premature closure in mice not expressing either EP4 or EP2 in the 
endothelium. D) In this model, PGE2/EP4 provides two functions. In its absence, the DA fails 
to mature. Second, as the vessel matures, PGE2 induced relaxation of the smooth muscle 
independent of the endothelium prevents premature closure. This model is consistent with the 
finding that mice lacking expression of EP4 in the smooth muscle die with a PDA, and mice 
lacking EP4 in the endothelium and EP2 in both endothelium and smooth muscle survive 
with no naïve phenotype.  
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Table 2.1. Survival of mice with smooth muscle, neural crest, or endothelial Ptger4 
deficiency. Neonates were monitored for 72 hours after birth. Deceased pups and cyanotic 
pups (requiring euthanasia) are shaded. Mendelian expectation of tissue specific EP4-
deficient animals is listed in brackets. Test of proportions between living and expected 
offspring was used to determine significance (p-value < 0.01). Test of proportions between 
surviving smooth muscle EP4-deficient animals (2/136) and surviving endothelial EP4-
deficient animals (53/60) was significant (p-value < 0.0001). 
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Ptger4+/- Tagln-Cre+/0 x 
Ptger4flox-neo/+ 35 20 18 30 20 33 27 39 0 20 [27] X 
Ptger4+/- Tagln-Cre+/0 x 
Ptger4flox-neo/flox-neo 14 - - 21 12 - - 24 0 10 [19] X 
Ptger4+/- Tagln-Cre+/+ x 
Ptger4flox-neo/flox-neo 3 - - - - - - 10 0 9 [10] X 
Ptger4+/- Tagln-Cre+/0 x 
Ptger4flox/flox 13 - - 29 29 - - 28 2 8 [29] X 
Ptger4+/- Tagln-Cre+/+ x 
Ptger4flox/flox 17 - - - - - - 56 0 47 [56] X 
Ptger4+/- Wnt1-Cre+/0 x 
Ptger4flox-neo/flox-neo 17 - - 32 35 - - 25 0 32 [31] X 
Ptger4+/- Wnt1-Cre+/0 x 
Ptger4flox/flox 10 - - 13 12 - - 16 0 8 [14] X 
Ptger4+/- Tek-Cre+/0 x 
Ptger4flox-neo/flox-neo 27 - - 52 39 - - 55 34 7 [49]  
Ptger4+/- Tek-Cre+/0 x 
Ptger4flox/flox 11 - - 33 22 - - 24 19 0 [26]  
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 Table 2.2. mRNA down regulated in the ductus arteriosus of full-term EP4 deficient pups as 
determined by Illumina Beadchip Mouseref-8. Differential expression stringency: p < 0.05, 
fold change >1.25. Transcripts regulated by or with SRF/MYOCD are annotated in bold (as 
defined by Ingenuity Pathway Analysis). Illumina ID transcript, Accession Number, Gene 
Symbol, Gene Name, Fold Change, and P-value are list. 
 
Illumina 
ID 
Public ID Gene 
Symbol 
Gene Name Fold 
Decrease 
P-value 
213948 NM_013645.2 PVALB parvalbumin alpha 15.12 0.0130 
213274 NM_011339.1 CXCL15 Chemokine (C-X-C motif) ligand 15 6.61 0.0000 
222704 NM_053087.1 EPGN Epithelial mitogen 4.68 0.0008 
218569 NM_177652 RYR3 Ryanodine receptor 3 4.65 0.0253 
212685 NM_027468 CPM Carboxypeptidase M 4.44 0.0000 
214286 NM_172928.1 Dcamkl3 Doublecortin and CaM kinase-like 3 3.02 0.0086 
194118 NM_007739 COL8A1 Collagen, type VIII, alpha 1 2.69 0.0000 
222158 NM_016754.3 MYLPF Myosin light chain, fast skeletal muscle 2.68 0.0135 
185125 NM_008728 NPR3 Natriuretic peptide receptor 3 2.50 0.0001 
214631 NM_029981 ADAMTSL2 ADAMTS-like 2 2.37 0.0000 
213216 NM_011824.1 GREM1 gremlin-1 2.34 0.0000 
223608 NM_028472.1 BMPER BMP-binding endothelial regulator 2.25 0.0000 
210459 NM_028133.1 EGLN3 EGL nine homolog 3 (C. elegans) 2.09 0.0000 
223402 NM_012028.2 SIAT7E Sialyltransferase 7E 1.97 0.0370 
214200 NM_026480.1 OOEP Oocyte expressed protein homolog (dog) 1.97 0.0426 
192308 NM_016873.1 WISP2 WNT1 inducible signaling pathway protein 2 1.97 0.0000 
189372 NM_024285 BVES Blood vessel epicardial substance 1.93 0.0000 
216487 NM_011570.2 TES Testis derived transcript, transcript variant 1,  1.89 0.0000 
190311 NM_011620.1 TNNT3 Troponin T3, skeletal, fast 1.89 0.0000 
211885 NM_016789.2 NPTX2 Neuronal pentraxin 2 1.86 0.0002 
209643 NM_008137.2 GNA14 Guanine nucleotide binding protein, alpha 14 1.85 0.0001 
211031 NM_011454.1 SERPINB6B Serine/cysteine peptidase inhibitor, B6b 1.84 0.0000 
212919 NM_010171.2 F3 Coagulation factor III 1.80 0.0000 
189991 NM_009306 SYT1 Synaptotagmin I 1.78 0.0013 
189308 NM_011618.1 TNNT1 Troponin T1, skeletal, slow 1.77 0.0356 
186897 NM_009994 CYP1B1 Cytochrome P450, 1b1 1.75 0.0001 
220885 NM_001126490 ISM1 Isthmin 1 homolog (zebrafish) 1.75 0.0000 
191670 NM_009405.1 TNNI2 Troponin I, skeletal, fast 2 1.73 0.0043 
188936 NM_009394.2 TNNC2 Troponin C2, fast 1.71 0.0188 
209151 NM_030888.2 C1QTNF3 C1q and tumor necrosis factor related protein 3 1.70 0.0046 
220036 NM_177914.1 DGKK Diacylglycerol kinase kappa 1.68 0.0038 
184867 NM_008357 IL15 Interleukin 15 1.67 0.0381 
194147 NM_199473 COL8A2 Collagen, type VIII, alpha 2 1.66 0.0000 
222248 NM_173767.2 INSC Inscuteable homolog (Drosophila) 1.64 0.0024 
195063 NM_016672 DDC Dopa decarboxylase 1.64 0.0223 
191471 NM_022322.2 TNMD Tenomodulin 1.63 0.0034 
214085 NM_013930.2 AASS Aminoadipate-semialdehyde synthase 1.62 0.0127 
219605 NM_172520.1 ARHGEF19 Rho guanine nucleotide exchange factor 19 1.62 0.0147 
209457 NM_198885.2 SCX Scleraxis  1.61 0.0000 
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212208 NM_181988.1 RERG RAS-like, estrogen-regulated, growth-inhibitor 1.59 0.0005 
221331 NM_007568.2 BTC Betacellulin, epidermal growth factor family 
member 
1.59 0.0008 
195636 NM_175177 BDH 3-hydroxybutyrate dehydrogenase, type 1 1.58 0.0089 
195145 NM_172496 COBL Cordon-bleu 1.58 0.0490 
184736 NM_145467 ITGBL1 Integrin, beta-like 1 1.57 0.0004 
224297 NM_011448 SOX9 SRY-box containing gene 9 1.54 0.0000 
196083 NM_024431 MORF4L1 Mortality factor 4 like 1 1.53 0.0233 
222264 NM_008342.2 IGFBP2 Insulin-like growth factor binding protein 2 1.53 0.0000 
193116 NM_011653 TUBA1 Tubulin, alpha 1A 1.53 0.0000 
195245 NM_008764.2 TNFRSF11B Osteoprotegerin 1.51 0.0004 
195482 NM_013560 HSPB1 Heat shock protein 1 1.51 0.0000 
222329 NM_016669.1 CRYM Crystallin, mu 1.51 0.0013 
219734 NM_008428.2 KCNJ8 Potassium inwardly-rectifying channel, J8 1.50 0.0001 
208654 NM_010233 FN1 Fibronectin 1 1.49 0.0004 
217063 NM_028608.1 GLIPR1 GLI pathogenesis-related 1 (glioma) 1.49 0.0000 
195643 NM_026993 DDAH1 Dimethylarginine dimethylaminohydrolase 1 1.49 0.0001 
189456 NM_029770 UNC5B Unc-5 homolog B (C. elegans) 1.48 0.0000 
210479 NM_178382.2 FLRT3 Fibronectin leucine rich transmembrane protein 3 1.48 0.0352 
210976 NM_013507.2 EIF4G2 Eukaryotic translation initiation factor 4, gamma 2  1.47 0.0146 
211631 NM_009194.1 SLC12A2 Solute carrier family 12, member 2 1.45 0.0006 
216622 NM_013657.4 SEMA3C Semaphorin 3C 1.45 0.0421 
214390 NM_010317.2 GNG4 Guanine nucleotide binding protein, gamma 4 
subunit 
1.44 0.0223 
221116 NM_172911.1 D8ERTD82E Pragmin 1.43 0.0027 
219038 NM_013519.1 FOXC2 Forkhead box C2 1.43 0.0000 
211222 NM_177757.3 Kif26b Kinesin family member 26B 1.43 0.0148 
223377 NM_008176.1 CXCL1 Chemokine (C-X-C motif) ligand 1 1.42 0.0025 
211787 NM_183390.1 KLHL6 Kelch-like 6 (Drosophila) 1.42 0.0005 
186672 NM_178804 SLIT2 Slit homolog 2 (Drosophila) 1.42 0.0000 
216680 NM_026639.1 ART4 ADP-ribosyltransferase 4 1.42 0.0001 
217103 XM_147272.1 SH3BGR SH3-binding domain glutamic acid-rich protein 1.42 0.0098 
208887 NM_010158.1 KHDRBS3 KH domain containing, signal transduction 
associated 3 
1.41 0.0181 
210760 NM_010016.1 CD55 CD55 antigen 1.41 0.0036 
217594 NM_009334.1 TCFAP2B Transcription factor AP-2 beta 1.40 0.0226 
221239 NM_022310.2 HSPA5 Heat shock 70kD protein 5 1.40 0.0006 
220853 NM_001033301 FHDC1 FH2 domain containing 1 1.39 0.0074 
221319 NM_011866.1 PDE10A Phosphodiesterase 10A 1.38 0.0456 
188577 NM_009451.3 TUBB4 Tubulin, beta 4 1.37 0.0000 
194409 NM_011706.1 TRPV2 Transient receptor potential cation channel, V2 1.37 0.0020 
220669 NM_152804.1 PLK2 Polo-like kinase 2 (Drosophila) 1.37 0.0000 
224263 NM_008430 KCNK1 Potassium channel, subfamily K, member 1  1.36 0.0117 
217240 NM_011857.2 ODZ3 Odd Oz/ten-m homolog 3 (Drosophila) 1.36 0.0006 
214953 XM_147213.1 SLC15A2 Solute carrier family 15 1.36 0.0294 
191087 NM_023908 SLCO3A1 Solute carrier organic anion transporter family 3a1 1.36 0.0078 
214528 NM_018884.1 PDZRN3 PDZ domain containing RING finger 3 1.35 0.0367 
220940 NM_172951.1 SNTG2 Syntrophin, gamma 2 1.35 0.0033 
210434 NM_008549.1 MAN2A1 Mannosidase 2, alpha 1 1.35 0.0008 
215425 NM_007689.2 CHAD Chondroadherin 1.35 0.0015 
209744 NM_146194 PICALM Phosphatidylinositol binding clathrin assembly 
protein 
1.35 0.0015 
219818 NM_011375.1 SIAT9 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 1.34 0.0072 
222438 NM_029825 SCFD1 Sec1 family domain containing 1 1.34 0.0486 
216305 NM_052973.1 STRN3 Striatin, calmodulin binding protein 3 1.34 0.0287 
217595 NM_172161.2 IRAK2 Interleukin-1 receptor-associated kinase 2 1.34 0.0002 
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223759 NM_133897.1 LRRC8C Leucine rich repeat containing 8 family, C 1.33 0.0364 
184420 NM_153541.1 ZBTB8 Zinc finger and BTB domain containing 8b 1.33 0.0337 
218073 NM_009468.1 DPYSL3 Dihydropyrimidinase-like 3 1.33 0.0006 
224057 NM_008542 SMAD6 MAD homolog 6 (Drosophila) 1.33 0.0001 
211657 NM_023056.2 TMEM176B Transmembrane protein 176B 1.33 0.0180 
220749 NM_010930.3 NOV Nephroblastoma overexpressed gene 1.33 0.0172 
186099 NM_153138.2 WASPIP WAS/WASL interacting protein family, member 1 1.32 0.0097 
220203 NM_172473.1 HACE1 HECT domain and ankyrin repeat containing, E3 
ubiquitin protein ligase 1 
1.32 0.0081 
224054 NM_011846 MMP17 Matrix metallopeptidase 17 1.32 0.0000 
194608 NM_178683 DEPDC1B DEP domain containing 1B 1.32 0.0002 
191350 NM_010818 CD200 CD200 antigen 1.32 0.0009 
220162 NM_008760.2 OGN Osteoglycin 1.31 0.0319 
223132 NM_008516.1 LRRN1 Leucine rich repeat protein 1, neuronal 1.31 0.0425 
193263 NM_011261 RELN Reelin 1.31 0.0011 
191790 NM_009416.2 TPM2 Tropomyosin 2, beta 1.31 0.0013 
219312 NM_008056 FZD6 Frizzled homolog 6 (Drosophila) 1.31 0.0074 
219275 NM_009386.1 TJP1 Tight junction protein 1 1.30 0.0057 
210306 NM_013834.1 SFRP1 Secreted frizzled-related protein 1 1.30 0.0002 
220981 NM_013846.2 ROR2 Receptor tyrosine kinase-like orphan receptor 2 1.30 0.0000 
213360 NM_011851.2 NT5E 5' nucleotidase, ecto 1.30 0.0166 
223065 NM_145438.1 LLGLH2 Lethal giant larvae homolog 2 (Drosophila) 1.30 0.0159 
187391 NM_025356.2 UBE2D3 Ubiquitin-conjugating enzyme E2D 3 1.29 0.0251 
220619 NM_009144.1 SFRP2 Secreted frizzled-related protein 2 1.29 0.0024 
189442 NM_023158 CXCL16 Chemokine (C-X-C motif) ligand 16 1.29 0.0090 
212800 NM_009911.2 CXCR4 Chemokine (C-X-C motif) receptor 4 1.28 0.0003 
219446 NM_027052.2 SLC38A4 Solute carrier family 38, member 4 1.28 0.0203 
219873 NM_007805.2 CYB561 Cytochrome b-561 1.28 0.0118 
190234 NM_139300 MYLK Myosin, light polypeptide kinase 1.27 0.0166 
218918 NM_175475.2 CYP26B1 Cytochrome P450, family 26, subfamily b, 
polypeptide 1 
1.27 0.0411 
221939 NM_207142.1 OLFR1036 Olfactory receptor 1036 1.27 0.0053 
210130 NM_183180.1 TSPAN18 Tetraspanin 18 1.27 0.0471 
212053 NM_013607.1 MYH11 Myosin, heavy polypeptide 11, smooth muscle 1.27 0.0234 
213358 NM_207663.2 DMN Synemin, intermediate filament protein 1.27 0.0338 
211655 NM_022316.1 SMOC1 SPARC related modular calcium binding 1 1.27 0.0090 
210097 NM_017380.1 SEPT9 Septin 9 1.27 0.0277 
221553 NM_025894.1 PSMD12 Proteasome 26S subunit, non-ATPase, 12 1.26 0.0061 
216383 NM_199307 ECE1 Endothelin converting enzyme 1 1.26 0.0181 
193870 NM_172294 SULF1 Sulfatase 1 1.26 0.0072 
222775 NM_007876.1 DPEP1 Dipeptidase 1 (renal) 1.26 0.0012 
186229 NM_027533 TSPAN2 Tetraspanin 2 1.26 0.0238 
212326 NM_008057.2 FZD7 Frizzled homolog 7 (Drosophila) 1.26 0.0008 
221274 NM_013470.1 ANXA3 Annexin A3 1.26 0.0000 
217605 NM_009145.1 NPTN Neuroplastin 1.26 0.0500 
192016 NM_016885 EMCN Endomucin 1.25 0.0002 
209161 NM_175206.2 Fbxl22 F-box and leucine-rich repeat protein 22 (Fbxl22),  1.25 0.0210 
223103 NM_007940.2 EPHX2 Epoxide hydrolase 2, cytoplasmic 1.25 0.0007 
193661 NM_021273 CKB Creatine kinase, brain 1.25 0.0000 
213347 NM_010718.1 LIMK2 LIM motif-containing protein kinase 2 1.25 0.0405 
213954 NM_016798.2 PDLIM3 PDZ and LIM domain 3 1.25 0.0000 
224105 NM_010336 LPAR1 Lysophosphatidic acid receptor 1 1.25 0.0159 
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Table 2.3. mRNA up regulated in the ductus arteriosus of full-term EP4 deficient pups as 
determined by Illumina Beadchip Mouseref-8. Differential expression stringency: p < 0.05, 
fold change >1.25. Transcripts regulated by or with SRF/MYOCD are annotated in bold (as 
defined by Ingenuity Pathway Analysis). Illumina ID transcript, Accession Number, Gene 
Symbol, Gene Name, Fold Change, and P-value are list. 
 
Illumina 
ID 
Public ID Gene 
Symbol 
Gene Name Fold 
increase 
P-value 
185459 NM_008797 PCX Pyruvate carboxylase 7.45 0.0377 
210568 NM_031180.1 KLB Klotho beta 5.32 0.0064 
214365 NM_001012322 SCTR Secretin receptor 4.88 0.0280 
218098 NM_178373.2 CIDEC Cell death-inducing DFFA-like effector c 3.88 0.0387 
221626 NM_009605.3 ACDC Adiponectin 3.85 0.0133 
219866 NM_153579.3 SV2B Synaptic vesicle glycoprotein 2 b 3.69 0.0058 
219899 NM_153170.1 SLC36A2 Solute carrier family 36, member 2 3.67 0.0450 
220351 NM_010271.2 GPD1 Glycerol-3-phosphate dehydrogenase 1 3.28 0.0159 
212767 NM_007606.2 CAR3 Carbonic anhydrase 3 3.14 0.0121 
224252 NM_010779 MCPT4 Mast cell protease 4 3.07 0.0005 
196155 NM_010923 NNAT Neuronatin 2.89 0.0295 
222851 NM_139134.1 CHODL Chondrolectin 2.72 0.0002 
223929 NM_133249 PPARGC1B Peroxisome proliferative activated receptor 2.60 0.0158 
220362 NM_008059.1 G0S2 G0/G1 switch gene 2 2.51 0.0170 
213896 NM_009328.1 TCF15 Transcription factor 15 2.42 0.0109 
218878 NM_008398.1 ITGA7 Integrin alpha 7 2.37 0.0012 
213154 NM_139292.1 REEP6 Receptor accessory protein 6 2.33 0.0082 
211772 NM_007498.2 ATF3 Activating transcription factor 3 2.30 0.0002 
222787 NM_008573 MCPTL Mast cell protease-like 2.26 0.0001 
189441 NM_023133 RPS19 Ribosomal protein S19 2.17 0.0216 
223923 NM_172119 DIO3 Deiodinase, iodothyronine type III 2.15 0.0069 
218703 NM_175520.2 GPR81 G protein-coupled receptor 81 2.10 0.0021 
212095 NM_007981.2 ACSL1 Acyl-CoA synthetase long-chain family member 1 2.05 0.0034 
219489 NM_024495.2 CAR13 Carbonic anhydrase 13 2.01 0.0043 
211789 NM_026384.2 DGAT2 Diacylglycerol O-acyltransferase 2 2.01 0.0206 
219556 NM_175268.3 FAM53B Family with sequence similarity 53 2.00 0.0238 
223998 NM_013738 PLEK2 Pleckstrin 2 1.84 0.0004 
216141 NM_001099635 MYH3 Myosin, heavy polypeptide 3, skeletal muscle 1.83 0.0000 
219547 NM_001081106 CYTL1 Cytokine-like 1 1.79 0.0000 
208882 NM_007469.2 APOC1 Apolipoprotein C-I 1.75 0.0456 
223331 NM_177304.2 ENPP6 Ectonucleotide pyrophosphatase/phosphodiesterase 
6 
1.74 0.0035 
185154 NM_020581 ANGPTL4 Angiopoietin-like 4 1.73 0.0163 
215880 NM_028448 CENPV Centromere protein V (Cenpv) 1.71 0.0240 
218383 NM_008819.2 PEMT Phosphatidylethanolamine N-methyltransferase 1.71 0.0265 
212300 NM_009255.2 SERPINE2 Serine (cysteine) peptidase inhibitor, clade E, 
member 2 
1.68 0.0001 
215026 NM_013558.1 HSPA1L Heat shock protein 1-like 1.68 0.0204 
216774 NM_008940.1 PRSS19 Kallikrein related-peptidase 8 1.67 0.0000 
216710 NM_146063.1 KRT79 Keratin 79 1.66 0.0359 
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211687 NM_178728.3 NAPEPLD N-acyl phosphatidylethanolamine phospholipase D 1.65 0.0291 
211016 NM_026730 GPIHBP1 GPI-anchored HDL-binding protein 1 1.63 0.0139 
223969 NM_027391 IYD  
Iodotyrosine deiodinase 
1.61 0.0221 
220490 NM_011157.1 SRGN Serglycin 1.61 0.0000 
221922 NM_009841.2 CD14 CD14 antigen 1.60 0.0356 
211007 NM_026071.1 SLC25A19 Solute carrier family 25 (mitochondrial thiamine 
pyrophosphate carrier), 19 
1.59 0.0368 
217499 NM_182805.1 GPT1 Glutamic pyruvic transaminase 1 1.59 0.0485 
213361 NM_009928.2 COL15A1 Procollagen, type XV 1.59 0.0000 
213165 NM_148938.2 SLC1A3 Solute carrier family 1 (glial high affinity glutamate 
transporter), member 3  
1.58 0.0104 
221505 NM_008002.3 FGF10 Fibroblast growth factor 10 1.58 0.0000 
220489 NM_178405.2 ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide  1.58 0.0020 
215064 NM_177157.2 GCHFR GTP cyclohydrolase I feedback regulator 1.57 0.0499 
213671 NM_133783.1 PTGES2 Prostaglandin E synthase 2 1.57 0.0080 
213534 NM_016745.2 ATP2A3 ATPase, Ca++ transporting 1.56 0.0223 
222768 NM_010698.2 LDB2 LIM domain binding 2 1.55 0.0000 
222379 NM_009744.2 BCL6 B-cell leukemia/lymphoma 6 1.54 0.0125 
214170 NM_022029.1 NRGN Neurogranin 1.52 0.0391 
215279 NM_026272.2 NARF Nuclear prelamin A recognition factor 1.51 0.0062 
186307 NM_025802 PNPLA2 Patatin-like phospholipase domain containing 2 1.50 0.0383 
211240 NM_007440.2 ALOX12 Arachidonate 12-lipoxygenase 1.49 0.0133 
220901 NM_027857.2 ACY3 Aspartoacylase (aminoacylase) 3 1.49 0.0014 
219921 NM_183263.1 RNMTL1 RNA methyltransferase like 1 1.47 0.0156 
214660 NM_026516.1 TMEM178 Transmembrane protein 178 1.46 0.0330 
196566 NM_145427.1 ATPAF2 ATP synthase mitochondrial F1 complex assembly 
factor 2 
1.46 0.0009 
185314 NM_028276 UTP14A UTP14, U3 small nucleolar ribonucleoprotein, 
homolog A 
1.45 0.0079 
192989 NM_009437.2 TST Thiosulfate sulfurtransferase 1.44 0.0208 
221099 NM_148945.1 RPS6KA3 Ribosomal protein S6 kinase polypeptide 3 1.44 0.0311 
215922 NM_025584.1 CD99 CD99 antigen 1.43 0.0001 
215936 NM_010924.1 NNMT Nicotinamide N-methyltransferase 1.42 0.0061 
208930 NM_029020.2 ADCB8 ATP-binding cassette, sub-family B, member 8 1.42 0.0412 
221447 NM_010095.2 EBF2 Early B-cell factor 2 1.42 0.0031 
213067 NM_145532.2 MALL Mal, T-cell differentiation protein-like (Mall) 1.42 0.0000 
192034 NM_175106 TMRM177 Transmembrane protein 177 1.40 0.0317 
220855 NM_053195.1 SLC24A3 Solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 3 
1.40 0.0000 
220374 NM_008787.2 PCNT2 Pericentrin 1.40 0.0061 
215729 NM_007913.2 EGR1 Early growth response 1 1.40 0.0063 
209344 NM_010780.1 MCPT5 Chymase 1 1.40 0.0423 
208987 NM_145070.2 HIP1R Huntingtin interacting protein 1 related 1.39 0.0000 
220888 NM_207649.1 DSCR1L1 Down syndrome critical region gene 1-like 1 1.39 0.0002 
215136 NM_026481.2 TPPP3 Tubulin polymerization-promoting protein family 
member 3 
1.39 0.0005 
223774 NM_183187.2 FAM107A Family with sequence similarity 107, member A 1.39 0.0501 
210091 NM_010046.2 DGAT1 Diacylglycerol O-acyltransferase 1 1.39 0.0062 
216902 NM_183405.1 COXVIB2 Cytochrome c oxidase subunit VIb polypeptide 2 1.38 0.0492 
192760 NM_025760 PTPLAD2 Protein tyrosine phosphatase-like A domain 
containing 2 
1.38 0.0430 
218536 NM_130884.1 IDH3B Isocitrate dehydrogenase 3 (NAD+) beta 1.38 0.0010 
213209 NM_009765.1 BRCA2 Breast cancer 2 1.37 0.0397 
188466 NM_053261 IMPA2 Inositol (myo)-1(or 4)-monophosphatase 2 1.37 0.0385 
214033 NM_183171.1 FEZ1 Fasciculation and elongation protein zeta 1 1.37 0.0003 
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224304 NM_175438 ALDH4A1 Aldehyde dehydrogenase 4 family, member A1 1.36 0.0046 
218477 NM_201230 FGFR1OP Fgfr1 oncogene partner 1.36 0.0157 
214816 NM_007409.2 ADH1 Alcohol dehydrogenase 1 (class I) 1.36 0.0098 
221458 NM_011338 CCL9 Chemokine (C-C motif) ligand 9 1.35 0.0413 
210330 NM_013723.2 PODXL Podocalyxin-like 1.34 0.0001 
219676 NM_033569.1 CNNM2 Cyclin M2 1.34 0.0006 
221353 NM_016894.1 RAMP1 Receptor (calcitonin) activity modifying protein 1 1.34 0.0001 
221373 NM_029083.1 DDIT4 DNA-damage-inducible transcript 4 1.33 0.0047 
213298 NM_011199.1 PTHR1 Parathyroid hormone receptor 1 1.33 0.0137 
218007 NM_011304.1 RUVBL2 RuvB-like protein 2 1.33 0.0000 
215828 NM_024177.2 MRPL38 Mitochondrial ribosomal protein L38 1.33 0.0003 
186695 NM_178655 ANK2 Ankyrin 2 1.33 0.0279 
211650 NM_010597.2 KCNAB1 Potassium voltage-gated channel, shaker-related 
subfamily, beta member 1  
1.32 0.0112 
187890 NM_026936 OXA1 Oxidase assembly 1-like 1.32 0.0199 
209664 NM_007669.2 CDKN1A Cyclin-dependent kinase inhibitor 1A (P21) 1.32 0.0001 
217974 NM_010218 FJX1 Four jointed box 1 1.32 0.0344 
195280 NM_145996 ARID5A AT rich interactive domain 5A 1.31 0.0477 
210469 NM_025285.1 STMN2 Stathmin-like 2 1.31 0.0225 
209971 NM_010474.1 HS3ST1 Heparan sulfate (glucosamine) 3-O-sulfotransferase 
1 
1.31 0.0030 
218963 NM_172753.2 CSGALNACT
1 
Chondroitin sulfate N-
acetylgalactosaminyltransferase 1 
1.31 0.0085 
210971 NM_028804 CCDC3 Coiled-coil domain containing 3 1.31 0.0000 
212280 NM_133928.1 CHCHD4 Coiled-coil-helix-coiled-coil-helix domain 
containing 4 
1.31 0.0181 
224113 NM_173408 DCN1 Defective in cullin neddylation 1 1.31 0.0119 
220989 NM_011898.2 SPRY4 Sprouty homolog 4 (Drosophila) 1.30 0.0019 
215445 NM_027203.2 LENG1 Leukocyte receptor cluster (LRC) member 1 1.30 0.0311 
221263 NM_197985.2 ADIPOR2 Adiponectin receptor 2 1.30 0.0137 
216450 NM_010863.1 MYO1B Myosin IB 1.30 0.0315 
218564 NM_179203.1 ATAD3A ATPase family, AAA domain containing 3A 1.30 0.0218 
217105 NM_021387.1 VSTM2B V-set and transmembrane domain containing 2B 1.29 0.0372 
210635 NM_008813.2 ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase 
1 
1.29 0.0291 
191042 NM_177574.1 YPS37D Vacuolar protein sorting 37D (yeast) 1.29 0.0255 
223606 NM_139198.1 PLAC8 Placenta-specific 8 1.29 0.0094 
219451 NM_008584.1 MEOX2 Mesenchyme homeobox 2 1.28 0.0324 
219627 NM_011577.1 TGFB1 Transforming growth factor, beta 1 1.28 0.0210 
195193 NM_178685 PCDH20 Protocadherin 20 1.28 0.0442 
193798 NM_178114 AMIGO2 Adhesion molecule with Ig like domain 2 1.28 0.0041 
220531 XM_126141.3 C1QTNF2 C1q and tumor necrosis factor related protein 2 1.28 0.0000 
223570 NM_013898.1 TIMM8A Translocase of inner mitochondrial membrane 8a1 1.28 0.0416 
213944 NM_016662.2 MXD3 Max dimerization protein 3 1.28 0.0212 
210167 NM_013415.2 ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide 1.28 0.0287 
224085 NM_173749 PAMR1 Peptidase domain containing associated with 
muscle regeneration 1 
1.28 0.0000 
219811 NM_008713.2 NOS3 Nitric oxide synthase 3, endothelial cell 1.28 0.0048 
212955 NM_138753.1 HEXIM1 Hexamethylene bis-acetamide inducible 1 1.27 0.0370 
214901 NM_013543.1 H2-KE6 H2-K region expressed gene 6 1.27 0.0003 
220032 NM_031196.1 SLC19A1 Solute carrier family 19 (sodium/hydrogen 
exchanger), member 1 
1.27 0.0207 
215908 NM_173370.3 CDS1 CDP-diacylglycerol synthase 1 1.27 0.0240 
192815 NM_177683.2 VGLL4 Vestigial like 4 (Drosophila) 1.27 0.0047 
216980 NM_023203.1 DCTPP1 dCTP pyrophosphatase 1 (Dctpp1) 1.27 0.0099 
211069 NM_053091.1 COX4I2 Cytochrome c oxidase subunit IV isoform 2  1.26 0.0024 
 68 
188390 NM_025407.2 UQCRC1 Ubiquinol-cytochrome c reductase core protein 1 1.26 0.0322 
212582 NM_010925.1 RRP1 Ribosomal RNA processing 1 homolog (S. 
cerevisiae) 
1.26 0.0342 
222660 NM_025314.1 DTD1 D-tyrosyl-tRNA deacylase 1 homolog (S. 
cerevisiae) 
1.26 0.0079 
217369 NM_019695 PARD6A Par-6 (partitioning defective 6,) homolog alpha 1.26 0.0437 
219624 NM_025928.1 PMF1 Polyamine-modulated factor 1 1.26 0.0019 
221027 NM_032003.1 ENPP5 Ectonucleotide pyrophosphatase/phosphodiesterase 
5 
1.25 0.0013 
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Table 2.4. Gene Functional Classification clustering by the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) of differentially expressed genes enriched 
in the A) wildtype ductus arteriosus and B) the EP4 deficient ductus arteriosus. 
 
A) 
Group 1   Enrichment Score: 3.6   
2481133 troponin i, skeletal, fast 2 
2456978 troponin c2, fast 
2636266 desmuslin 
2482209 tropomyosin 2, beta 
2469018 troponin t3, skeletal, fast 
2460136 troponin t1, skeletal, slow 
  
Group 2  Enrichment Score: 1.79  
2734097 betacellulin, epidermal growth factor family member 
1215807 gli pathogenesis-related 1 (glioma) 
1259365 endomucin 
1259470 riken cdna 1810009m01 gene 
1246836 frizzled homolog 7 (drosophila) 
1223849 cd200 antigen 
1234698 tetraspanin 2 
1243429 tenomodulin 
2702016 riken cdna 2010011i20 gene 
1227699 riken cdna 2610042g18 gene 
2726030 cdna sequence ab023957 
1248696 leucine rich repeat containing 8 family, member c 
2774854 endothelial differentiation, lysophosphatidic acid g-protein-coupled receptor, 2 
1235735 riken cdna 5830414c08 gene 
1229788 coagulation factor iii 
2728493 blood vessel epicardial substance 
  
Group 3  Enrichment Score: 1.63  
2754551 dipeptidase 1 (renal) 
2636285 5' nucleotidase, ecto 
2773800 matrix metallopeptidase 17 
2629191 carboxypeptidase m 
  
Group 4  Enrichment Score: 1.1  
2602185 septin 9 
1236175 tubulin, beta 4 
2613740 cdna sequence bc056349 
2494251 tubulin, alpha 1 
2597778 guanine nucleotide binding protein, alpha 14 
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4B) 
Group 1   Enrichment Score: 1.82   
1256673 ubiquinol-cytochrome c reductase core protein 1 
2612178 cytochrome c oxidase subunit iv isoform 2 
2611532 solute carrier family 25 (mitochondrial deoxynucleotide carrier), member 19 
1229627 cytochrome c oxidase subunit vib polypeptide 2 
  
Group 2  Enrichment Score: 1.09  
2722716 atpase, na+/k+ transporting, alpha 2 polypeptide 
2638017 atpase, ca++ transporting, ubiquitous 
2602902 atpase, na+/k+ transporting, beta 2 polypeptide 
2590908 atp-binding cassette, sub-family b (mdr/tap), member 8 
2727777 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 
  
Group 3  Enrichment Score: 1.03  
2675232 protease, serine, 19 (neuropsin) 
1240746 mast cell protease 4 
1248718 chymase 2, mast cell 
1227947 riken cdna e430002g05 gene 
2594908 mast cell protease 5 
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ABSTRACT 
 
Objective - Prostaglandin E2 (PGE2) has a well-established role in controlling patency of the 
ductus arteriosus (DA). Neonatal PGE2 infusion maintains DA patency, and pharmacological 
inhibition of PGE2 production can result in DA closure. Common inbred mouse strains 
deficient in the prostaglandin E2 receptor 4 (EP4) or hydroxyprostaglandin dehydrogenase 
(HPGD) succumb to fatal persistent patency of the DA. The genetic inheritance of PDA in 
humans is far more complex, indicating the existence of several modifiers or redundant 
pathways that contribute to DA closure.  
 
Methods and Results - Here we report a recombinant inbred (RI) mouse strain that exhibits 
PGE2 independent DA maturation and closure. The RI strain was derived from selective 
breeding of EP4+/- mice until EP4 deficient survival rates of 70% were achieved. The RI 
mice undergo DA closure during subcutaneous injection of PGE2, the loss of HPGD, or the 
loss of both cyclooxygenase isozymes. 
 
Conclusions - The loss of EP4, HPGD, or COX, and pharmacological inhibition of PGE2 
production indicates that the DA is capable of prostanoid-independent maturation and 
closure. 
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INTRODUCTION 
 
 Most of the blood flow through the fetal circulatory system of placental mammals 
bypasses the pulmonary system via the ductus arteriosus (DA) and foramen ovale. At birth, 
when the placenta can no longer provide the site of gas exchange, the cardio-pulmonary 
system of the neonate must quickly remodel from the fetal, pulmonary bypassing system, 
into the adult circulatory system. A primary component of this cardiovascular transition is the 
constriction and permanent remodeling of the DA [1]. The DA shunts blood from the right 
ventricle to the descending aorta, allowing nearly all the blood ejected from the right 
ventricle to bypass the pulmonary system. During in utero development, the patent DA and 
foramen ovale allow the four chambers of the heart to develop while allowing blood flow to 
bypass the pulmonary system. At birth, the air filled lungs offer less resistance to pulmonary 
blood flow, and increased pulmonary blood output causes an increase in left atrial pressure 
resulting in physical closure of the foramen ovale. An increase in oxygen tension and a 
decrease in plasma PGE2 levels coincide with DA closure.  
Human neonatal care has demonstrated the importance of prostaglandin E2 (PGE2) for 
DA maturation and closure. At birth, a newborn’s plasma PGE2 levels drop as pulmonary 
circulation catabolizes plasma PGE2. A pharmacologically induced drop in PGE2 via 
cyclooxygenase inhibition, can also trigger closure whether it is given maternally resulting in 
premature in utero DA closure, or neonatally in an attempt to initiate closure of the DA [2]. 
Conversely, neonatal infusion of PGE2 maintains patency of the DA [3].  
Genetic disruption of various components of prostaglandin metabolism and signaling 
has further refined the role of prostaglandins in DA maturation and closure. The loss of the 
 77 
PGE2 subtype 4 receptor (Ptger4; EP4) leads to persistent PDA in common inbred mouse 
strains (CIMS), resulting in congestive heart failure within the first 24 hours of life [4]. The 
loss of cyclooxygenase-2 (COX-2) increases incidence of PDA, and the loss of both 
cyclooxygenase isozymes (COX-1 and COX-2) results in 100% morbidity of pups prior to 
any DA remodeling [5]. Genetic disruption of hydroxyprostaglandin dehydrogenase 
(HPGD), the main catabolizing agent of PGE2, results in fatal PDA in CIMS [6]. CIMS with 
either insufficient PGE2 levels (COX deficiency), loss of EP4 receptor expression, or lack of 
quick PGE2 catabolism (HPGD deficiency) succumb to cardiovascular failure due to a 
persistent PDA.  
In larger mammals the inheritance of PDA is a polygenic trait and numerous 
molecular and environmental components may play a role in DA closure [7]. The inheritance 
of PDA in CIMS is simple; disruption of any part of PGE2/EP4 signaling results in PDA. 
Here we present a selectively bred recombinant inbred (RI) mouse strain that exhibits 
PGE2/EP4 independent DA maturation and closure that potentially represents the additional 
molecular components responsible for the complex genetic inheritance of PDA seen in higher 
mammals.  
 
 METHODS 
 
Generation of Recombinant Inbred Strain with Prostaglandin Independent DA Closure 
Disruption of the Ptger4 locus by targeted homologous recombination in 129/Ola 
embryonic stem cells is described elsewhere [4]. 129 chimeras were mated to (C57BL/6 x 
DBA/2)F1 females, yielding a mixed genetic background (MB) carrying 129, DBA/2, and 
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B6 alleles. Intercrossing MB littermates generated rare Ptger4-/- mice that survived to 
adulthood. Surviving Ptger4-/- mice were mated to Ptger4+/- siblings. Brother-sister mating 
continued for >30 generations with selection for Ptger4-/- survival generated a recombinant 
inbred (RI) mouse line.  
 
Genome Wide SNP Scan 
Purified genomic DNA was used for whole genome panel of 768 SNPs using the 
Illumina GoldenGate platform at the Mutations Mapping and Development Analysis Project 
(MMDAP) directed by Jennifer Moran and David Beier at Brigham and Women's Hospital, 
Harvard Medical School in collaboration with The Broad Institute Center for Genotyping and 
Analysis. Of the 768 SNPs on the panel, 694 are informative for the three founding strain 
(129, C57BL/6, and DBA/2) of the RI mouse line. 
 
Histology of Ductus Arteriosus 
Full-term (E18.5) females were euthanized and fetuses collected. Neonatal pups were 
obtained from full-term females that were observed at E19 for the initiation of natural 
delivery. Birth of the third pup was designated as time point zero. At 4 hours or 18 hours 
after birth pups were euthanized. In euthanized fetuses and euthanized pups, thoracotomy 
was performed to expose the DA. Whole body 10% formalin fixation was used to fix the DA 
in situ. Following fixation, the DA was removed, cryo-sectioned, and H&E stained. 
 
Transgenic Mice and Breeding 
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The generation of mouse lines with targeted disruptions of the EP1 receptor, EP2 
receptor, EP3 receptor, thromboxane receptor, prostacyclin receptor, HPGD, Cox-1, and 
Cox-2 is described elsewhere [6, 8-14]. All mice were maintained on a C57BL/6 genetic 
background until crossed to the RI strain. RI Ptger4-/- mice were crossed to C57BL/6 mice 
carrying a null allele of one the other genes of interest (EP1, EP2, EP3, prostacyclin receptor, 
thromboxane receptor, HPGD, COX-1, and COX-2). Offspring were backcrossed to RI mice 
using Ptger4-/- survival as a selection marker. Once Ptger4-/- survival rates equaled that of the 
parental RI Ptger4-/- mice (~4 generations of backcrossing), sibling-sibling crosses were 
setup to generate mice deficient in both the EP4 receptor and the other gene of interest. 
Survival of HPGD deficient mice was assessed in the presence and absence of the EP4 
receptor. Survival of RI Cox-1-/- Cox-2-/- mice was assessed in mice that expression the EP4 
receptor. Neonates were observed for the presence of a DA related phenotype for the first 96 
hours after birth. The DA status of deceased pups was determined at time of death. Pups were 
euthanized at first instance of any pulmonary distress (cyanosis, dyspnea, etc.)  
 
Maternal Indomethacin Treatment 
Indomethacin (Sigma) was diluted in 17mM Na2CO3, 125mM Na2HPO4 (pH 7.2) to 
1mg/ml. Indomethacin was intravenously administered at 1mg/g body weight to full term 
females. Two hours after indomethacin administration, mothers were sacrificed and fetal DA 
status was determined. 
 
Neonatal PGE2 treatment 
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Prostaglandin E2 (Cayman Chemical #14010) was freshly prepared by dissolving 1mg 
lyophilized PGE2 in 2ml of sterile Dulbecco’s phosphate buffered saline (DPBS), yielding 
0.5mg/ml PGE2. Two hours and four hours after natural birth, a subcutaneous injection of 
5µg PGE2 or 10µl of vehicle (DPBS) was administered to neonates. At 8 hours after natural 
birth, neonatal DA patency was determined. In neonates that died prior to 8 hours or that 
required euthanasia due to pulmonary distress, DA status was determined at that time. 
 
Quantitative RT-PCR 
Total RNA was isolated from tissues using RNeasy Minikit or Microkit (Qiagen). 4-8 
ductus arteriosi of identical genotype were pooled prior to extraction of RNA. Reverse 
transcription of RNA to cDNA for quantitative RT-PCR was performed using a high-
capacity cDNA archive kit (Applied Biosystems) according to the manufacturer’s 
instructions. Primers and probes were purchased from Applied Biosystems. All reactions 
were performed with TaqMan PCR Universal Master Mix (Applied Biosystems) using the 
Applied Biosystems 7900 HT Fast Real-Time PCR System. Reactions were performed in 
duplicate in a 20µl volume using 10ng of cDNA. Expression level of genes of interest was 
normalized to either Beta-2 microglobulin (B2M) or GAPDH levels. Data were analyzed 
using the comparative CT method as described by Applied Biosystems. 
 
Statistical Analysis 
 Statistical analysis was performed using Prism 4 (GraphPad Software). Comparisons 
of the median were made by Mann Whitney U test unless otherwise noted. Data are shown as 
median ± S.E.M. Differences with p<0.05 were considered statistically significant and 
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denoted with a *. Statistical significance of survival rates and response to pharmacological 
agents was determined by test of proportions. 
 
 
RESULTS 
 
RI Mouse Strain with Prostaglandin Independent DA closure 
On the 129S6, C57BL/6, MRL, FVB, and DBA/2 genetic backgrounds, the loss of the 
EP4 receptor results in near complete penetrance of persistently patent DA leading to 
congestive heart failure within the first 24 hours of life. EP4 receptor loss in all hybrids 
analyzed, (129xB6)F1, (129xDBA)F1, and (B6 x DBA)F1, also resulted in fatal PDA. Over 
400 CIMS and F1 litters were analyzed for EP4 deficient survivors (Table 3.1). Of the 2120 
pups that survived to 5 days of age, only 12 pups were EP4 deficient (1.7% of Mendelian 
expectation). The few surviving EP4 deficient animals did not transmit EP4 deficient 
survival to their offspring.  
The 129/Ola Ptger4 chimeras were bred to (DBA/2 and C57BL/6)F1 mice. Each 
strain individually and pairwise results in fatal PDA in the absence of the EP4 receptor 
(Table 3.1). However, intercrossing of the Ptger4 hemizygous mixed background mice 
resulted in a 5% survival rate of Ptger4-/- pups (data not shown). The mixed background EP4 
deficient animals were bred to Ptger4+/- siblings. Further sibling-sibling mating generated a 
RI strain with EP4 deficient survival rates of 70%. EP4 deficient survival rates vary 40-100% 
from the same cohorts (data not shown). After 35 generations of selective sibling-sibling 
mating, survival rates have remained constant for the last 20 generations. 
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Genome Wide SNP Scan 
Genome wide SNP genotyping of several sub-lines of the RI strain was used to 
determine if any of the three founding strains was preferentially selected or if heterozygosity 
at specific loci was crucial for EP4 deficient survival. Three sub-lines were analyzed (Figure 
3.1). By F32, all 694 informative SNPs were homozygous in the RI strain (Table 3.2).  
 
DA closure in the RI strain 
A delay in DA closure was observed in EP4 deficient RI pups (Figure 3.2). The 
closure delay is estimated to be no more than 3-5 hours. To prevent maternal rejection, which 
can affect DA closure, the pups were not marked in order of birth, therefore the precise 
hourly age of pups is uncertain. After 24 hours, the EP4 deficient pups that have undergone 
closure are indistinguishable from wildtype littermates. EP4 deficient animals that had not 
undergone closure by 24 hours were either deceased or cyanotic from cardiovascular failure 
requiring euthanasia. Ultimately, the DA of RI EP4 deficient pups closes and remodels into 
the ligamentum arteriosum, indistinguishable from wildtype littermates. 
 
Mice deficient in EP4 and other prostanoid receptors 
Three additional PGE2 receptors are expressed in arterial vessels [15]. It was initially 
theorized that functional redundancy in the PGE2 receptors was compensating for the loss of 
the EP4 receptor and allowing DA closure in the RI strain. Ptger4 has the most significant 
differential expression in the DA compared to the aortic arch, but the other three PGE2 
receptors (Ptger1-3) are nevertheless expressed in the DA (Figure 3.3).  
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EP3 is a Gi-protein coupled receptor that causes a decrease in intercellular cAMP 
levels. RI Ptger3-/- Ptger4-/- animals were indistinguishable from the parental RI Ptger4-/- 
mice. The EP1 receptor is Gq-protein coupled, signaling the phosphatidylinositol-calcium 
second messenger system. RI Ptger1-/- Ptger4-/- animals are indistinguishable from the 
parental RI Ptger4-/- mice. The EP2 receptor was thought to be the most likely compensatory 
receptor because both the EP2 and EP4 receptors are Gs-protein coupled receptors, stimulate 
adenylate cyclases, cause smooth muscle relaxation [16]. RI Ptger2-/- Ptger4-/- animals did 
not have any neonatal phenotype, and underwent DA closure identical to that of the parental 
RI mice. 
Other prostanoid receptors have been implicated in DA maturation and closure. 
Prostacyclin I2 is produced by the DA, and therefore the prostacyclin receptor (IP), a Gs-
protein couple receptor, was considered a possible compensatory receptor [17]. RI IP-/- 
Ptger4-/- mice survive to adulthood with no naïve phenotype. The thromboxane receptor 
(TP), a Gq-protein coupled receptor, may also play a role in DA closure, since TP receptor 
antagonism increase the relaxation affect of PGE2 [18]. The RI Ptger4-/- TP-/- mice survive to 
adulthood with no naïve phenotype. (See Table 3.3 for survival rate of RI mice) 
 
Mice deficient in hydroxyprostaglandin dehydrogenase 
C57BL/6 mice deficient in hydroxyprostaglandin dehydrogenase (HPGD), the 
primary catabolizing agent of PGE2, succumb to pulmonary distress and die with PDA within 
the same time frame as EP4 deficient CIMS [6]. RI Hpgd-/- mice survive to adulthood. HPGD 
deficient survival rates were similar in both Ptger4+/- and Ptger4-/- mice. In mice lacking the 
EP4 receptor, it is not surprising that the loss of ligand catabolism would have no affect. 
 84 
However, RI mice with a functional EP4 receptor showed no phenotypic differences in the 
presence or absence of HPGD.  
 
Pharmacological control of DA patency 
To validate the hypothesis that a PGE2-independent mechanism was responsible for 
DA closure in the RI strain, PGE2 levels were controlled pharmacologically in RI full term 
fetuses and neonates. Indomethacin was administered to 129 and RI full term (18.5E) 
females (Figure 3.4). EP4 deficient fetuses had no response to maternal indomethacin 
treatment. Fetuses with a functional EP4 receptor underwent in utero closure of the DA.  
Mimicking human neonatal care, exogenous PGE2 will maintain patency of the DA in 
neonatal mice. To confirm the loss of PGE2 sensitivity for maintaining patency in the RI 
strain, PGE2 was subcutaneous injected into 129 wildtype, RI Ptger4+/-, and RI Ptger4-/- 
neonates (Table 3.4). In 129 wildtype neonates, PGE2 maintained ductal patency through out 
the first 12 hours of life, at which point morbidity with PDA was near 100%. In RI Ptger4+/- 
neonates, PGE2 maintained DA patency for the first 10 hours of life at which point DA 
closure was seen in ~50% of the pups. RI Ptger4-/- neonates had no response to PGE2 
injections and underwent DA closure by 12 hours after natural birth. 
 
Mice Deficient in Cyclooxygenase 
On a mixed genetic background of C57BL/6J and 129/Ola, Cox-1-/- Cox-2-/- mice die 
shortly after birth prior to DA closure [5]. The Cox-1 and Cox-2 loci were independently 
breed to the RI strain, using EP4 deficiency survival as a selection marker. After 4 
generations of back crossing, the Cox-1 and Cox-2 line were in-crossed to generate Cox-1+/- 
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Cox-2+/- cohorts. From these cohorts, 1 in 16 pups are COX deficient. Ultimately, male mice 
heterozygous for one isozyme and deficient in the other were utilized to increase the 
incidence of Cox deficient pups to 1 in 8. Females were heterozygous for both isozymes due 
to the previously reported breeding defects observed in both Cox-1-/- and Cox-2-/- females 
[19]. In the RI strain, COX deficient pups undergo DA closure (Table 3.5). Life expectancy 
of the COX deficient mice ranges from 24 hours to 2 weeks.  
 
 
DISCUSSION 
 
The evidence presented here indicates that DA maturation and closure can occur 
independent of prostaglandins. This prostaglandin-independent mechanism is parallel to the 
PGE2/EP4-dependent mechanism. The RI wildtype mice support this since the in utero DA is 
sensitive to indomethacin induced PGE2 depletion in the majority of fetuses (Figure 3.4), and 
neonatal PGE2 administration does not maintain DA patency in all the pups (Table 3.4). A 
superficial discrepancy exists between the neonatal PGE2 induced patency seen in some of 
the RI wildtype pups and the DA closure of RI Ptger4+/+ Hpgd-/- pups. Persistent patency 
following exogenous PGE2 treatment in RI mice can be attributed to either the highly 
variable penetrance of prostanoid-independent DA closure, or possibly a decreased efficacy 
of the prostanoid-independent mechanism to rescue pups that have initiated, but aborted, the 
prostaglandin-dependent DA closure. The latter scenario is similar to the increased incidence 
of PDA in full-term neonates that were exposed to indomethacin in utero [20, 21]. Therefore, 
once PDA closure is initiated but is unsuccessful or aborted, a second attempt of DA closure 
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may be less likely to succeed. CIMS rely exclusively on the PGE2/EP4 mechanism and 
succumb to fatal PDA when any component of PGE2/EP4 signaling is dysfunctional. The RI 
mice utilize the PGE2/EP4 mechanism when available, but are able to utilize a secondary 
mechanism of closure if the prostanoid mechanism does not initiate successful DA closure.  
Survival of RI EP4+ HPGD- pups is further evidence that this secondary mechanism 
acts constitutively and in parallel to the prostanoid dependent mechanism of DA closure. 
There is no known role of HPGD in DA maturation, and in CIMS deficient in HPGD 
pharmacological depletion of plasma PGE2 levels is sufficient in initiating DA closure in 
neonates [6]. The RI Ptger4+/+ Hpgd-/- mice develop in utero with functional PGE2/EP4 
signaling, and it is not until after birth that the loss of HPGD becomes a factor. However, the 
RI Hpgd-/- pups are able to undergo DA closure without indomethacin treatment. This further 
indicates that the initiating signal for closure in this secondary mechanism is PGE2 
independent.  
Survival of cyclooxygenase deficient animals further solidifies the theory that 
prostanoid independent closure is occurring in RI mice. The development of the DA in COX 
deficient fetuses likely occurs in chronically decreased levels of PGE2 since PGE2 can be 
transported through the placental barrier from the mother, but the pup lacks the ability to 
produce their own PGE2 [22, 23]. Although this results in death quickly after birth prior to 
DA closure in CIMS deficient in COX, the RI mice survive the perinatal period and undergo 
DA closure and remodeling, despite the absence of any paracrine effects of localized PGE2 
production in the DA [24].  
In a murine-centric context, this secondary method of DA closure would appear to be 
novel. However, human and canine genetic studies have shown that DA closure is a complex 
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trait that is difficult to attribute to a single mechanism. There are several lines of canines that 
have a high incidence of PDA, but 100% penetrance of PDA has not been achieved [7]. The 
genetics of human PDA is limited to analysis of family pedigrees that have high incidence of 
PDA in full term deliveries. Several consanguineous Iranian families have a significantly 
increased frequency of PDA; 3 fold increase over the general Iranian population [25]. QTL 
mapping in these families has shown a high LOD score (>6) for a chromosomal region of 
approximately 34 genes, one of which is a phospholipase precursor. Phospholipases are a 
class of enzymes responsible for the deacylation and release from the plasma membrane of 
arachidonic acid, the sole substrate for cyclooxygenase enzymes, which is a rate limiting step 
in all downstream prostanoid production [26]. Increased incidence of PDA was seen in a 
human population with a recessive mutation in the HPGD gene [27]. Although the mutation 
is predicted to completely abolish HPGD activity, penetrance of PDA is less than 40% in 
individuals carrying two copies of the null allele. This is drastically different than what is 
observed in CIMS, in which HPGD loss causes 100% penetrance of PDA. However, the 
incidence of PDA in the human population does mimic the increased incidence of PDA that 
we observe in the RI HPGD deficient mice. 
Spontaneous resolution of untreated human PDA is likely to be prostanoid-
independent. Patients with untreated PDA that survive early childhood, have a 0.5% yearly 
rate of spontaneous closure. Spontaneous DA closure has not been linked to any specific life-
event [28]. At birth, high PGE2 levels of late gestation quickly drop, and O2 tension in the 
DA increases due to left-to-right shunting through the DA of oxygen-rich left ventricular 
output. In adults, prostaglandins have a very active role in maintaining homeostasis and 
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hypoxia in the aorta is rare, therefore there is no proposed mechanism for spontaneous adult 
DA closure.  
We have shown that there is a parallel prostanoid independent mechanism of DA 
closure. In the RI mice, the prostanoid independent mechanism of DA closure has been 
separated from the dominant prostanoid dependent mechanism. Elucidating the mechanism 
of this prostanoid-independent closure has the potential of being exploited as another 
pharmacological target to initiate DA closure, where as currently only NSAIDs that inhibit 
Cox activity are used. We have also shown here that there is an initiating event for DA 
closure that does not involve PGE2 depletion. It is probable that the non-prostanoid 
mechanism was marginalized in the mouse by either evolution or by selective breeding that 
has yielded the commercially available CIMS. The survival of a few EP4 deficient CIMS 
mice on various genetic backgrounds indicates that the prostanoid independent mechanism in 
the RI strain is not the result of a novel mutation but rather the selective breeding to re-
establish in the mouse a higher penetrance for the secondary prostanoid independent 
mechanism for DA closure that is seen in other mammals. Commercial CIMS have a low 
penetrance of prostanoid independent DA closure making them unusable in the study of the 
complex prostanoid independent mechanism active in higher mammals. In the RI strain, this 
is resolved since the mice can rely exclusively on the prostanoid independent mechanism for 
DA closure.  
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 Figure 3.1. Pedigree of the recombinant inbred (RI) mouse line used for genome wide 
SNP genotyping. Top grey box represents the mating of a male 129/Ola chimera and a 
(B6/DBA/2)F1 female. EP4 deficient mice were genotyped from F8, F22, F27, F31, and F32 
generations (grey and black ovals).  
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Figure 3.2. DA closure in the RI strain in the presence and absence of the EP4 receptor. The 
DA from full-term fetus, new born (< 4 hours old), and older neonate (12-18 hours old) in the 
presence and absence of the EP4 receptor were H&E stained. No gross morphological 
difference was observed between the EP4+ and EP4- animals. A delay of DA closure (<3 
hours) was observed in the EP4 deficient animals. Delay is possibly only an artifact due of 
birthing process. Ultimately, the DAs of EP4 deficient animals close and form a ligamentum 
arteriosum, indistinguishable from wildtype animals.  
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Figure 3.3. Quantitative RT-PCR demonstrating relative expression of the four PGE2 
receptors in 129 wildtype fetal ductus arteriosus and fetal aortic arch. Expression level for 
each receptor is individually standardized to expression level in the aortic arch. * p < 0.05 
 
 
 
 92 
Figure 3.4. In utero DA closure following maternal indomethacin treatment. Indomethacin 
was intravenously administered at 1µg/g body weight to 18.5-day pregnant mice. Two hours 
later, the fetal DA was scored based on ratio of inner diameter of DA to pulmonary duct (PD) 
into one of three categories: Patent (DA:PD ~ 1.0), Partial constriction (DA:PD < 0.5), and 
Closed (DA:PD < 0.1). In utero constriction of the DA was seen in the majority of EP4+ 
fetuses (22/47 closed, 41/47 constricted). EP4 deficient fetuses had no DA response to 
maternal indomethacin treatment. Significance was confirmed by test of proportions of RI 
EP4+ (26/32 DA constricted) and RI EP4- (0/15 constricted), p-value < 0.01. 
 
  
129 EP4+ RI EP4+ RI EP4-
Closed
Partial
Patent
47% 47%
19%
34%
100%
53%
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Table 3.1. EP4 deficient survival rates in on various genetic backgrounds. For CIMS and F1 
litters, number of expected EP4 deficient pups were determined based on the number of 
EP4+/+ and EP4+/- pups surviving, which account for 75% of a litter based on Mendelian 
segregation of the wildtype and null locus. For the RI litters, the expected number of EP4 
deficient animals is calculated from the Mendelian expectation from a combination of 
breeding types (+/- x +/- and -/- x +/-). Significance of observed versus expected determined 
by test of proportions. CIMS EP4 deficient survival (12/703) and RI EP4 deficient survival 
(404/577) differences were statistically significant (p-value < 0.0001) 
 
 
EP4 Deficient Significant  
Strain Litters  Pups  Observed Expected % 
p-value 
<0.01 
129S6 166 724 4 240 2% X 
C57BL/6 70 344 1 114 1% X 
DBA/2 42 178 1 59 2% X 
MRL 13 72 1 24 4% X 
FVB 13 72 0 24 0% X 
129 x B6 51 393 4 130 3% X 
129 x DBA 32 166 0 55 0% X 
B6 x DBA 30 171 1 57 2% X 
CIMS 417 2120 12 703 2% X 
RI 174 1189 404 577 70% X 
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Table 3.2. SNP genotyping of RI mice from 5 generations of three sub-lines. The mouse 
from generation F8 was a sibling of the single common ancestors of all RI sub-lines. Percent 
identity between the five generations genotyped is displayed. Percent homozygousity across 
genome within the genotyped animal is indicated in shaded squares.  
 
 
 F8 F22 F27 F31 F32 
F8 65.6% 50.4% 49.6% 50.6% 51.0% 
F22   90.2% 58.8% 61.0% 61.1% 
F27    99.1% 95.5% 96.0% 
F31     99.4% 98.7% 
F31         100% 
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 Table 3.3. Survival of (A) RI mice deficient in the EP4 receptor and one other prostanoid 
receptors, (B) and survival of HPGD deficient RI mice. Test of proportions used to calculate 
significance of observed versus expected number of pups surviving > 5 days. 
 Mice surviving >5 days 
Observed 
vs 
Expected 
 Pup Genotype Litters  Pups  Observed Expected % p-value 
A) Ptger4-/- IP-/- 42 255 59 63 94% 0.376 
 Ptger4-/- Ptger1-/- 8 56 11 15 73% 0.244 
 Ptger4-/- Ptger2-/- 305 1462 312 348 90% 0.108 
 Ptger4-/- Ptger3-/- 40 184 51 57 89% 0.313 
 Ptger4-/- TP-/- 3 21 3 4 75% 0.364 
B) Ptger4-/- Hpgd-/- 9 63 14 16 88% 0.374 
 Ptger4+/? Hpgd-/- 11 78 17 21 81% 0.375 
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Table 3.4. Exogenous PGE2 treatment of pups within the first 2 hours after natural birth to 
maintain DA patency. Each neonate received a series of two injections; at 2 hours after 
natural birth, and a second injection two hours later. Littermates were given vehicle control. 
Four hours later, patency of the DA was determined. Pups deceased prior to 8 hours, had DA 
patency status assessed at time of death. DA patency in 129 mice (7/8) was statistically 
different (p-value < 0.01) from DA patency in RI mice (5/20). Vehicle was not statistically 
significant; 0/7 versus 3/11, p-value = 0.13. 
 
      DA Status @ 8 hours   
Strain EP4 Treatment Patent Constricted Morbidity 
129S6 + PGE2 7 1 4/8 
129S6 + Vehicle 0 7 1/7 
RI + PGE2 2 5 2/7 
RI + Vehicle 1 2 0/3 
RI - PGE2 3 10 2/12 
RI - Vehicle 2 6 1/8 
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Table 3.5. 24-hour survival rate and DA closure in Cox-1-/-, Cox-2-/-, and Cox-1-/- Cox-2-/- RI 
mice. Survival of Cox deficient animals (7/117) is not statistically significant from expected 
(15/125), p-value = 0.104. 
 
Parental Genotype: Total Pups @ 24 hours 
(±/- ±/-) x (+/- +/-) Deficient Pups 
Pup Genotype Litters 
Total 
Pups 
w/ DA 
closed Expected 
Dead w/ 
PDA or ? 
Cox-1-/- 21 183 52 37 1 
Cox-2-/- 18 131 34 32 3 
Cox-1-/- Cox-2-/- 15 117 7 15 5 
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 The closure of the ductus arteriosus (DA) is an essential component in the transition 
from fetal circulation to adult circulation. A better understanding of DA maturation and 
closure can lead to the development of additional treatments for PDA. Currently, the use of 
non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit cyclooxygenase (COX) activity is 
the only non-invasive treatment for PDA. Neonatal NSAIDs treatment carries several 
potential side affects, some of which can be life threatening in premature infants. 
 The use of prostaglandins to control DA patency has become common practice in 
neonatal care. PGE2 infusion to maintain DA patency is critical for the survival of infants 
with severe congenital heart disease that is dependent on shunting through the DA. 
Indomethacin (and recently other NSAIDs) have good efficacy in initiating DA closure. 
However, despite the routine use of prostaglandin to control the DA, the mechanisms 
responsible for normal maturation and closure of the DA are still unknown. 
 In the work presented here, we generated a conditional null allele of the EP4 receptor, 
which is critical for DA closure in most mammals. Animals with tissue specific-loss of the 
EP4 receptor were generated with the use of various Cre recombinase transgenes. The loss of 
EP4 receptor expression on smooth muscles resulted in cardiovascular failure due to a 
persistently patent DA, similar to EP4 deficient animals. Given the unique and abundant 
expression of EP4 by the smooth muscle of the DA, it was not surprising that smooth muscle 
loss would lead to a DA-related phenotype. 
 Prior to the generation of endothelial EP4 deficient animals, it was difficult to predict 
the phenotypic consequences of EP4 receptor loss in all endothelial cells of the body. EP4 is 
expressed by the endothelium of all arterial vessels, including the DA. The lack of any 
neonatal phenotype in endothelial EP4 deficient mice was surprising. Although, we did not 
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predict that fatal PDA would necessarily occur in these mice, I assumed that the endothelium 
played some role in DA maturation and closure. However, maternal indomethacin treatment 
resulted in identical in utero DA closure in wildtype and endothelial EP4 deficient fetuses. 
 Although the EP4 receptor expression in smooth muscle is unique and critical for its 
closure, the EP2 receptor has been shown to have an overlapping physiological role in the 
adult animal [1]. To eliminate receptor redundancy in the endothelium we generated 
endothelial EP4 deficient animals on an EP2 deficient genetic background. Somewhat 
surprisingly, mice lacking EP4 and EP2 expression in the endothelium have no naïve 
phenotype. The loss of both known PGE2 dilatory receptors, EP2 and EP4, in the 
endothelium indicates that their expression is non-essential in development or in the 
unchallenged adult. Future use of the EP2-/- EP4flox/- Tek-cre mice will include the 
measurement of the vasodilatory affects of exogenous PGE2. If PGE2-induced dilation is 
abolished or greatly attenuated, it will indicate that vasodilatory affects of PGE2 occur via the 
endothelium of arterial vessels. However, if PGE2-induced dilation is unaffected, it will show 
that PGE2’s vasodepressant role occurs outside the arterial vessel network, likely in the 
kidney. 
 We confirmed that PGE2 signaling via the endothelium of the DA or smooth muscle 
EP2 receptors has no consequences on DA closure. Gene expression profiling of EP4 
deficient and wildtype DA was used to assess the transcriptional consequences of EP4 
receptor expression. Since the smooth muscle media of the murine DA accounts for most of 
the physical mass of the DA, the gene expression profile largely represents the transcriptional 
consequences of EP4 receptor signaling in the smooth muscle. Lower noise levels may be 
achieved in microarray analysis from neural crest EP4 deficient DAs, perhaps even on a EP2 
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null genetic background. These mice still succumb to fatal PDA, but PGE2 signaling, or lack 
there of, would be limited to the smooth muscle layer of the DA. 
 Genes differentially up-regulated in the EP4 null DA showed no consistent pattern, 
whether through visual inspection of the gene list or pathway analysis through programs such 
as Database for Annotation, Visualization and Integrated Discovery (DAVID). The working 
theory had been that EP4 expression is exerting a positive transcriptional affect in the DA, 
and therefore activating the machinery necessary for DA maturation and closure. If this 
premise is assumed accurate, then the lack of pattern in genes up regulated in the EP4 null 
DA is not surprising. However, accepting half a premise is not an option, therefore, we must 
also assume that genes up regulated in the wildtype DA will reveal a consistent pattern. 
Pathway analysis of genes up regulated in the wildtype DA revealed enrichment for 
cytoskeletal-related genes. Discovering that a smooth muscle arterial vessel has cytoskeletal 
gene expression is not itself a breakthrough. However, when the original EP4 null locus was 
generated by our lab over 10 years ago, close comparison of the wildtype and EP4 null DA 
revealed no apparent morphological difference [2]. EM analysis did not reveal any gross 
difference in morphology between the DA that was destined to close (wildtype), and the DA 
destined to stay patent (EP4 null). The lack of morphological differences is not in itself 
surprising if one takes into account that most cytoskeletal genes were up regulated by less 
than 50% in the wildtype. Expression of cytoskeletal genes by other great arteries is 
substantial, therefore an increased expression due to EP4 receptor expression in the DA may 
be difficult to detect, especially if subtle. 
Further corroboration of the microarray data is necessary before victory can be 
declared in the war of discerning the role of the EP4 receptor in the DA. Validation via 
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realtime RT-PCR can easily be accomplished, but would still rely on transcript levels rather 
than protein levels. Semi-quantitative immunofluorescence or immunohistrochemistry may 
yield protein-based validation for the microarray data, but it is difficult to predict the 
likelihood of success. Semi-quantitative measurements in immunostaining techniques are 
readily performed when expression of a particular protein is either abolished or greatly 
increased compared to reference sample. However, the gene expression profile of the DA 
indicates that most of the cytoskeletal genes, at the transcriptional level, are not greatly 
increased in the wildtype DA.  
One option is to utilize gene transfer in cultured aortic smooth muscle cells [3]. The 
aorta and DA share a neural crest lineage and morphologically the vessels appear similar. 
However, at birth the EP4 expressing DA constricts while the non-expressing aorta has no 
discernable reaction to the drop in plasma PGE2 levels and an increase in O2 tension. 
Adenovirus facilitated expression of the EP4 receptor in aortic smooth muscle would 
potentially mimic DA smooth muscle. If the forced expression of the EP4 receptor in 
cultured aortic smooth muscle results in an increase in cytoskeletal proteins, the role of PGE2 
signaling in the DA would be clear. Alternatively, the neural crest specific Wnt-1 promoter 
can be used to generate a neural crest specific EP4 transgene that would force artificial 
expression of the EP4 receptor in the smooth muscle of most great arteries of the heart. If the 
EP4 receptor expression is the primary molecular component responsible for differentiating 
the DA from the other great arteries of the heart, then forced expression of the EP4 receptor 
in the smooth muscle of the common carotid artery, brachiocephalic artery, and ascending 
aorta may have extremely deleterious effects on the vessels following birth as the vessels 
attempt to constrict and close similar to the DA. Physiologically, the contractility of the 
 106 
wildtype and EP4 deficient murine DA can also be tested. The model proposed here would 
predict that in utero the full-term wildtype DA would have a stronger contraction force than 
the EP4 deficient DA when constricted by KCl [4]. Physiological manipulation of the DA 
could confirm if the wildtype DA has an increased contractility due to EP4 signaling. 
However, this would still leave the possibility that the EP4 receptor is allowing maturation of 
the DA, and increased contractility is an indirect by-product of the EP4 receptor induced 
maturation.  
Corroboration of cytoskeletal gene up-regulation in the EP4-expressing smooth 
muscle of the DA would strengthen the model that EP4 receptor signaling is responsible for 
two distinct roles in the DA. PGE2-induced dilation of the neonatal DA can maintain patency 
and most studies have shown that this is facilitated through the EP4 receptor.  The second 
role of the EP4 receptor is increasing expression of contractile proteins during late gestation. 
After birth, when endogenous PGE2 levels are depleted, the EP4 receptor has no role in 
closure and becomes a passive participant, since it provides neither dilatory signal nor 
metabolic signal in the absence of ligand. However, the up-regulated cytoskeletal protein 
with the absence of PGE2 induced dilation can constrict the vessel. Unique expression of the 
EP4 receptor in the smooth muscle DA is an ingenious system for linking DA maturation to 
gestation, and DA closure to birth. In late gestation, plasma PGE2 levels are at their highest, 
coinciding with the maturation of the DA. Relying on the same receptor for both metabolic 
growth and dilation allows for the coupling of these functions. As metabolic signaling 
increase contractility of the DA, dilatory signals increase maintaining patency. At birth, the 
DA is hopefully mature and metabolic signals via the EP4 receptor are unnecessary, and the 
loss of dilatory signals via the EP4 receptor allows for smooth muscle constriction. 
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 If the consequence of PGE2/EP4 signaling in the smooth muscle DA is an increase in 
cytoskeletal proteins, and possibly increased contractility of the vessel, how does 
prostaglandin-independent closure occur? The recombinant inbred (RI) mouse strain 
described here undergoes DA maturation and closure independent of the EP4 receptor. The 
loss of either COX isozymes of HPGD does not prevent DA closure, either of which is fatal 
on isogenic mouse backgrounds. Preliminary data also indicates that DA closure occurs even 
in RI mice deficient in all four PGE2 receptors. If the survival of EP1-4 deficient animals is 
validated, this would indicate that PGE2 is non-essential in mouse development. The RI 
strain has indicated that PGE2 depletion is not the initiating event in DA closure, as in utero 
indomethacin exposure has no affect on the fetal DA. Given the fact that the mechanism of 
DA closure in isogenic mice is still unclear, determining a second mechanism will be a 
challenge. 
 It has been recently shown that the loss of myocardin in the neural crest results in 
non-symptomatic fatal PDA in mice [5]. Expression of myocardin induces the transcription 
of numerous cytoskeletal genes, similar to the enrichment seen in mircroarray analysis of the 
wildtype DA. The disruption of myocardin in the neural crest of the RI strain could possibly 
indicate where in the pathway of DA maturation and closure the prostanoid-independent 
mechanism play a role. If it is confirmed that EP4 receptor expression in the DA stimulates 
cytoskeletal genes, and the RI mice succumb to fatal PDA following neural crest myocardin 
loss, then a prostanoid independent mechanism of closure is likely to be very similar to the 
prostanoid-dependent mechanism. However, if neural crest myocardin loss does not restore 
fatal PDA in RI mice, then the prostanoid-independent mechanism is truly distinct from the 
prostanoid-dependent mechanism.  
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 Gene expression profiling of the DA from RI fetuses in the presence and absence of 
the EP4 receptor would shed more light on the nature of DA closure in the RI mice. If the 
expression profile of the RI EP4 deficient DA is similar to the 129 wildtype DA, at least in 
terms of cytoskeletal genes, then that would support the theory that the RI mice are simply 
inducing expression of the same genes but independent of the EP4 receptor. 
 Another option for determining the nature of the prostanoid-independent mechanism 
of DA closure in the RI strain would be quantitative trait locus analysis. Crossing the RI 
strain to common inbred mouse line (in which EP4 loss is fatal), and then backcrossing that 
F1 to the parental RI line would generate EP4 deficient animals on a mixed genetic 
background. From previous studies, most of the N2 EP4 deficient animals succumb to fatal 
PDA. However, N2 EP4 deficient survivors do occur. Genome wide SNP analysis of the N2 
EP4 deficient animals that survive versus those that succumb to PDA could be used to 
determine the loci that may play a role in the inheritable prostanoid-independent DA closure 
in the RI strain. 
 A caveat should be mentioned for both QTL and gene expression profiling in the RI 
strain. Low-resolution genome wide SNP genotyping has shown that the RI strain is 
homozygous at all loci by F32, and EP4 survival rates have remained constant for over 20 
generations. However, the prostanoid-independent mechanism of DA closure has highly 
variable efficacy, even in litters from the same cohorts. This variable survival creates noise, 
which would necessitate an increase in the number of replicates in QTL or expression 
analysis to eliminate that noise. 
 The noise is best illustrated through an example. If a microarray analysis is done on 
the pooled total RNA from 4 EP4 deficient in utero ductii, but 25% of those pups would have 
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died after birth due to fatal PDA, then potentially only 3 of the 4 ductii will be expressing the 
genes necessary for EP4-independent DA closure. A similar situation is created in QTL 
analysis. If a comparison is made between EP4 deficient survivors and non-survivors, then 
the population of non-survivors includes individual animals that had inherited the loci 
necessary for DA closure but succumbed to PDA due to the variable efficacy of prostanoid-
independent closure. 
 In summary, the work we have presented here has shown that there is a dual role for 
PGE2/EP4 signaling in the smooth muscle, a dilatory role and a metabolic role. We have also 
shown that this signaling is non-essential in murine DA closure, and the initiation of closure 
is not exclusively dependent on catabolism of PGE2 by the pulmonary system. An alternative 
signal initiating DA closure independent of plasma PGE2 depletion can potentially be 
exploited as an alternate pharmacological target for the treatment of PDA in neonates. If 
PGE2 signaling does have a metabolic role in the DA, then extra-uterine maturation of the 
DA of premature infant may be possible by exogenous PGE2, which will hopefully result in 
DA constrict without the need of surgical or NSAIDs intervention. 
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